Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514449000 - Oxygen containing hetero ring

514451000 - The hetero ring is six-membered

514453000 - Polycyclo ring system having the hetero ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514458000 Tocopherols (e.g., vitamin E, etc.) 69
514457000 Coumarins (including hydrogenated) 26
Entries
DocumentTitleDate
20120202876METHODS OF TREATING DISEASES WITH PROANTHOCYANIDIN OLIGOMERS SUCH AS CROFELEMER - Disclosed herein are methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer. Also disclosed is the anti-secretory effect of crofelemer on Calcium-activated chloride channels (CaCC) and Cystic fibrosis transmembrane conductance regulator (CFTR).08-09-2012
20110028541LUBIPROSTONE CRYSTAL, THE USE AND THE METHOD FOR THE PREPARATION THEREOF - The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction pattern of said crystal comprises characteristic peaks measured at the following 2θ reflection angles: 14.6±0.2°, 17.0±0.2° and 19.6±0.2°. As compared to amorphous lubiprostone, the crystal of the present invention has the advantages of relative high purity, stable properties and easy-for-storage and use.02-03-2011
20130030045METHOD OF PREVENTING AND TREATING OSTEOPOROSIS - The invention discloses a method of preventing and treating osteoporosis. The method comprises a step of enhancing osteoblast differentiation and inhibiting osteoclast differentiation by administering a pharmaceutically effective amount of a composition comprising 6-hydroxy flavone compound or 7-methoxy flavone compound, or at least one pharmaceutically acceptable salt thereof to a subject.01-31-2013
20090197943Flavonoid Dimers and Methods of Making and Using Such - Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers are developed in this invention, which are linked together by linker groups of various lengths. These flavonoid dimers are found to be efficient P-gp modulators that increase cytotoxicity of anticancer drugs in vitro and dramatically enhance their intracellular drug accumulation. It is found that the flavonoid dimers of this invention is also useful in reducing drug resistance in treating parasitic diseases.08-06-2009
20120172424CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.07-05-2012
20100022633Cognitive abilities improving agent - A composition containing bark extract from the genus 01-28-2010
20100113586PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF MENOPAUSAL SYMPTOMS - Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.05-06-2010
20100076071USE OF EQUOL FOR TREATING SKIN DISEASES - Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.03-25-2010
20130030047Fatty Acid Derivatives of Catechins and Methods of Their use - The present disclosure relates to fatty acid derivatives of green tea catechins including epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and their epimers (e.g., catechin, catechin gallate, gallocatechin, gallocatechin gallate) or their mixtures and/or green tea extracts.01-31-2013
20130030046USE OF BLACK SOYBEAN HULL EXTRACTS IN MANUFACTURE OF PRODUCTS FOR PREVENTING AND TREATING OSTEOARTHRITIS - The application relates to a use of black soybean hull extracts in the manufacture of foods, health care products and medicaments. The black soybean hull extracts can be added to foods or drinks, and also can be made into all kinds of oral health care products and oral medicaments used by conventional methods of preparing traditional Chinese medicine preparations. The products can significantly improve symptoms of osteoarthritis, and also can stabilize or even reverse the degradation of cartilage of osteoarthritis.01-31-2013
20130079393ISOFLAVONE FATTY ACID ESTER DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USES THEREOF - Isoflavone fatty acid ester derivatives of formula (I) or (II), the preparation method thereof and the pharmaceutical compositions containing such compounds are disclosed. The uses of such compounds in preparation of medicaments for preventing or treating hyperlipidemia, obesity or type II diabetes are also disclosed.03-28-2013
20130035382Anti-Viral Compounds - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.02-07-2013
20130035381VIRUS-INACTIVATING COMPOSITION CONTAINING LOW-MOLECULAR WEIGHT COMPOUND AND ARGININE - The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass % of an extract solution of natural product.02-07-2013
20130041023Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract - The present invention relates to a composition for preventing or treating rotavirus infection, comprising a licorice extract, fractions thereof or compounds separated therefrom. The licorice extract, fractions thereof or compounds separated therefrom have anti-rotavirus effects and exhibit not only virucidal effects against various rotaviruses, but also the effect of inhibiting the cytopathic effect of rotaviruses. Thus, the composition can be effectively used for the prevention or treatment of rotavirus infection.02-14-2013
20130035379Compositions for Inhibiting Protine-Directed Protein Kinase Fa/Glycogen Synthesis Kinase 3 Alpha and Use Thereof - The invention provides a composition for inhibiting proline-directed protein kinase F02-07-2013
20100041746NOVEL USE OF ORGANIC COMPOUNDS - The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function. Other fields of use are disorders connected to impaired lipid metabolism, impaired glucose metabolism and impaired insulin action, obesity, overweight conditions, eating disorders such as bulimia and anorexia nervosa, cardiovascular diseases, atherosclerosis, vascular diseases, heart failure, inflammatory disorders such as arthritis, rheumatoid arthritis, osteoarthritis, gout, gastrointestinal disorders such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis, skin related conditions such as psoriasis, eczema, burns, dermatitis, and allergy, respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic diseases, and/or bone disorders such as osteoporosis and osteopenia. The compounds may also be used for bodyshaping, for improving the muscle:fat ratio or for accelerating skin wound healing. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of treating the above mentioned disorders/diseases in mammals including humans and to the compounds of the formula I themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the treatment of such disorders/diseases as mentioned above.02-18-2010
20090124685AGAVE SYRUP EXTRACT HAVING ANTICANCER ACTIVITY - The present invention comprises an 05-14-2009
20090156662Fat Absorption Inhibitor - Disclosed is a composition or beverage/food for inhibiting the fat absorption, which is derived from a natural material and therefore is safe, and which can be ingested continuously. The composition or beverage/food comprises the following components: (A) theaflavine monogallate; (B) theaflavine; (C) theaflavine digallate; and (D) polyphenol, wherein these components satisfy the following requirements: (1) a weight-based content ratio [(A)/(B)] is 0.4-100%; (2) the weight of the component (A) is larger that that of the component (C); and (3) a weight-based content ratio [A)/(D)] is 0.01-1.0%. The composition or beverage/food can be used for the prevention or treatment of a disease such as arteriosclerosis and an ischemic heart disease (e.g., angina pectoris, myocardial infarction).06-18-2009
20100105766COMPOSITION FOR INHIBITION OR PREVENTION OF BONE DENSITY REDUCTION - The present invention relates to a composition for the inhibition or prevention of a bone mineral density reduction, or food and drink for use in such application, comprising isoxanthohumol or an isomerized hop extract as an active ingredient. According to the present invention, a bone mineral density reduction can be inhibited or prevented while avoiding a problem of side effect which may be induced by using an estrogen preparation.04-29-2010
20100105767COMPOUNDS, COMPOSITIONS AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.04-29-2010
20100093844ORAL COMPOSITION FOR ENHANCING SKIN PROPERTIES - A stable consumable emulsion, comprising at least 50% water, 0.2 to 3 wt % of an oil comprising at least 12 wt % of docosahexaenoic acid and eicosapentaenoic acid, an antioxidant, a flavouring and at least 0.01 wt % food-grade phospholipid emulsifier is provided which provides noticeable improvements in skin when consumed regularly.04-15-2010
20080269320Cocoa Extracts - Disclosed and claimed are cocoa extracts such as polyphenols or procyanidins, methods for preparing such extracts, as well as uses for them, especially as antineoplastic agents and antioxidants. Disclosed and claimed are antineoplastic compositions containing cocoa polyphenols or procyanidins and methods for treating patients employing the compositions. Additionally disclosed and claimed is a kit for treating a patient in need of treatment with an antineoplastic agent containing cocoa polyphenols or procyanidins as well as a lyophilized antineoplastic composition containing cocoa polyphenols or procyanidins. Further, disclosed and claimed is the use of the invention in antioxidant, preservative and topiosomerase-inhibiting compositions and methods.10-30-2008
20130046011HOT-MELT EXTRUDED COMPOSITIONS CONTAINING PLANT-DERIVED PHENOLIC MATERIALS AND PROCESSES FOR THE PREPARATION THEREOF - A hot-melt extruded composition is disclosed that includes about 20-80% wt. of a plant-derived phenolic material; about 20-85% wt. of one or more edible or bioerodible excipients; about 0-40% wt. of a surface active material; about 0-40% wt. of an oral absorption enhancer; and about 0-10% wt. of one or more pharmaceutical or food grade additives. The composition has been hot-melt extruded at a temperature substantially below the melting point of the plant-derived phenolic material to produce a hot-melt extruded composition wherein substantial degradation of the plant-derived phenolic material has not occurred.02-21-2013
20130090378PROCESS FOR EXTRACTING COMPOUND FROM CRANBERRY LEAVES AND RELATED PRODUCTS - Provided are methods of producing proanthocyanidin (PAC)-containing solutions, powders, and beverages, as are PAC-containing solutions, powders, and beverages produced thereby and cranberry plant material products.04-11-2013
20130072551USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.03-21-2013
20130059907WOGONIN-CONTAINING PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER STEM CELLS GROWTH AND APPLICATION THEREOF - A pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and an application thereof are disclosed. The pharmaceutical composition includes: a wogonin compound; and a pharmaceutically acceptable carrier. The application is the use of the wogonin compound to manufacture a medicament for inhibiting cancer stem cells growth or carcinoma metastasis.03-07-2013
20120309822TREATMENT OF INFECTIOUS DISEASES - The present invention relates to the treatment or prevention of infectious disorders, and to tonabersat or an analogue of formula (1), and compositions comprising tonabersat or an analogue of formula (1) for use in said treatments.12-06-2012
20110015261USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS - A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep disorder. The composition should be given in such an amount that it causes a less than 40% decrease in the amount of aMT6s in complete nocturnal urin. The composition can be a combination treatment comprising a specific beta-blocker in combination with another known drug e.g., melatonin with similar effect for treatment of insomnia.01-20-2011
20090292013In-Situ Forming Implant for Animals - The invention relates to a composition, comprising a thermoplastic polymer, a rate modifying agent and a biologically active agent, useful as a slow-release drug-delivery implant in the body of a human or animal that can be administered in liquid form into the body.11-26-2009
20090082429Antimicrobial Compositions and Methods of Use - A catechin is modified in at least one position (most preferably in the 3-position of the C-ring) to increase its lipophilicity. Contemplated catechins are demonstrated to have significantly improved antibacterial properties, likely due to catastrophic membrane damage.03-26-2009
20090076129METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of 03-19-2009
20110046215ABNORMAL INTRAOCULAR PRESSURE TREATMENT - Methods and compositions for reducing intraocular pressure in a patient, particularly a human patient, are described. In particular, compositions are disclosed that contain an anthocyanoside or an extract comprising it, a proanthocyanidin or an extract comprising it and combinations thereof. The compositions are useful for lowering intraocular pressure.02-24-2011
20120115944USE OF CARNITINE AND DIHYDROQUERCITIN TO POSITIVELY INFLUENCE THE NATURAL PIGMENTATION PROCESS - A method for positively influencing the natural pigmentation process of skin or appendages thereof includes topically contacting the skin or appendages thereof with a combination of carnitine and/or a derivative thereof with dihydroquercetin and/or a derivative thereof.05-10-2012
20120115943COMPOSITION AND METHOD FOR NEUROPROTECTION AGAINST EXCITOTOXIC INJURY - The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea polyphenols in preventing or treating clinical excitotoxic injury such as brain trauma, brain ischemia, epilepsy, and Alzheimer's disease.05-10-2012
20080207747Lipase Inhibitors - The present invention provides lipase inhibitors containing flavan-3-ol monomers or acylates thereof derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of flavan-3-ol monomers represented by the formula:08-28-2008
20090012156Composition comprising polyphenol - A fat based spread or a dairy based drink comprising from to 1 wt % of isorhamnetin can advantageously be used to control blood pressure. It has been found that these products have an effect on vasorelaxation.01-08-2009
20090012155Composition Of Skin External Application For Anti-Aging - The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.01-08-2009
20100087519USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES - Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.04-08-2010
20130165506PULEGANIC ACID INSECT REPELLENT - The present invention relates to compositions of puleganic acid, and the use thereof as a topical treatment for skin, such as a repellant for insects or arthropods.06-27-2013
20080300301Composition for Promoting Production of Hyaluronic Acid Containing Kaempferol and Quercetin - Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin. Kaempferol and quercetin of the invention increase an expression of a hyaluronic acid synthase (HAS) gene existing in a skin cell line of human epidermis, thereby promoting a production of hyaluronic acid in the human cell. Accordingly, the composition containing at least one of kaempferol and quercetin according to the invention can be usefully used as a cosmetic composition for increasing skin elasticity and preventing skin dryness or aging, or a pharmaceutical composition for treating or preventing a degenerative arthritis.12-04-2008
20090042975Process For The Production Of Botanic Extracts - Disclosed is a process for the production of botanic extracts containing at least 15% by weight of oligomeric proanthocyanidins of the OPC A2 type, comprising: (a) subjecting shells of the fruit of 02-12-2009
20100331401ANTIMICROBIAL AND ANTIINFLAMMATORY COMPOSITION - The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.12-30-2010
20100160426CRYSTALLINE GENISTEIN SODIUM SALT DIHYDRATE - The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.06-24-2010
20090298933ORAL COMPOSITION CONTAINING EGCG AND LYCOPENE - Composition containing the combination of (−)-epigallocatechin gallate (EGCG) and lycopene characterized in that the ratio of EGCG to lycopene is in the range of 100:1 to 1:1.12-03-2009
20110130449Assay for Monitoring Activity of Jmjd6 - The invention provides a method for assaying Jmjd6 activity.06-02-2011
20090054517Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment - A new method is provided for inhibiting tumor growth and for delaying the onset of cancer. Several estrogenic compounds from plants are capable of inhibiting cell proliferation both in cell cultures and in whole animals. These compounds likely exert their anti-proliferation effects by inhibiting the Hedgehog signaling pathway. Estrogen receptors may also play an essential role in the inhibitory effect of these compounds.02-26-2009
20110144196TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF - Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.06-16-2011
20090118359Food product - A method for the treatment of a bioflavonoid composition, comprising the contacting of the bioflavonoid composition with ethanol of at least 90% purity at a temperature of from 10 to 80° C. for a period of at least 0.5 hour, followed by separation of the ethanol and the bioflavonoid, wherein the contacting comprises the solubilisation of the bioflavonoid in the ethanol and whereby the separation involves the recrystallisation of the bioflavonoid and whereby the contacting takes place in the presence of active carbon in an amount of 1-10 wt % based on the bioflavonoid.05-07-2009
20110130448FUNCTIONALIZED PHENOLIC ESTERS AND AMIDES AND POLYMERS THEREFROM - The present invention relates to a compound of the formula:06-02-2011
20100063139USE IN A COSMETIC COMPOSITION OF LIPOCHROMAN-6 TO ENHANCE THE RADIANCE OF THE COMPLEXION OF THE SKIN, ESPECIALLY THE SKIN OF THE FACE - The invention relates to the use, in a cosmetic composition intended for topical application to the skin, of lipochroman-6 as an active intended to enhance and/or restore the radiance of the complexion of the skin, especially the skin of the face.03-11-2010
20100190845METHOD OF TREATING CANCER USING ATP SYNTHASE INHIBITORS - The present invention is directed to a method of treating cancer in a subject in need of such a treatment by administering an inhibitor of ATP synthase in a pharmaceutically effective amount, preferably, the inhibitor contains one pyrone ring. The present invention also provides for a pharmaceutical composition comprising an inhibitor of ATP synthase, preferably, the inhibitor is aurovertin B.07-29-2010
20090076131Anti-Cancer and Anti-Inflammatory Effects of Annurca Apple Extracts and Compositions Purified Therefrom - The present invention includes compositions and methods for modulating cell proliferation using a pharmaceutical effective amount of an isolated and purified polyphenolic composition having one or more polyphenolic compounds extracted from one or more plant tissues, specifically from one or more tissues of the Annurca apple.03-19-2009
20110301232PROCESS OF EXTRACTING PROCYANIDINS BY ALKALINE HYDROLYSIS - A process of extracting procyanidins by alkaline hydrolysis. In particular, a procyanidin-containing material, pomace or residue is treated with an alkali, such as sodium or potassium hydroxide, for a predetermined amount of time and at a predetermined temperature to release procyanidins bound to polysaccharides and/or proteins of the cell wall or depolymerize polymeric procyanidins. After the procyanidins are released by alkaline hydrolysis, the extracts are acidified to obtain a pH level where the procyanidins do not degrade. The process of extracting procyanidins may be utilized to estimate the total amount of bound procyanidins in a plant material, enhance the bioavailability of beneficial procyanidins monomers and/or to treat the residue remaining after conventional solvent extraction for increased procyanidin extraction.12-08-2011
20130023582Method of Disinfection or Infection Control Against Norovirus - An anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus. The anti-norovirus agent includes, as an active ingredient, an extract from a plant of the genus 01-24-2013
20100137424PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL OR A NEBIVOLOL ANALOGUE - The disclosed pharmaceutical compositions for oral administration comprising as the active medicinal ingredient nebivolol, a nebivolol analogue or a pharmaceutically acceptable acid addition salt thereof and a wetting agent. The ratio of the wetting agent to the active ingredient is less than 0.025. The application also relates to methods of preparing these compositions and using said compositions for treating coronary vascular disorders in humans.06-03-2010
20090247621Diosmetin compounds, a process for their preparation and pharmaceutical composition containing them - Compounds of formula (I):10-01-2009
20100331399POLYPHENOL EXTRACTION PROCESS - The invention relates to a process for extracting one or more polyphenols from fruits such as apples and to uses of said extracts in the treatment or prophylaxis of cardiovascular disease, colon cancer and digestive health.12-30-2010
20090298932COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.12-03-2009
20120190736METHOD OF MANAGING BRONCHO-CONSTRICTIVE CONDITION - The present disclosure is in relation to the use of a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s), in management of broncho-constrictive conditions such as Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).07-26-2012
20090286869Flavanols and B-Type Procyanidins and Inflammation - The invention relates to compositions, and methods of use thereof, containing certain polyphenols such as flavanols, procyanidins and derivatives thereof for treating inflammation and/or inflammation-related or associated disease or condition, and/or for the relief of pain, in a subject sensitive to a selective cyclooxygenase-2 (COX-2) inhibitor and/or a subject sensitive to a COX-nonselective nonsteroidal anti-inflammatory drug (NSAID).11-19-2009
20090099255Agent for Alleviating Vascular Failure - [Object] In recent years, life style-related diseases, particularly circulatory system diseases caused by the tendency toward high caloric diet, the change in life style, lack of exercise, stress and so on increased and have became a serious social problem. These diseases are caused mainly by injures in blood vessels. To prevent injures in blood vessels, there has been required a vascular endothelial cell-protecting agent and a food having an effect of protecting vascular endothelial cells.04-16-2009
20110263697Methods of Reducing Oxidative Modification of a Muscle Cell Protein - The present invention is directed to methods for reducing oxidative modification of one or more proteins or other cellular constituents involved in muscle cell contraction, for reducing muscle fatigue or for increasing muscle performance.10-27-2011
20100113584NOVEL USE OF (-)-EPIGALLOCATECHIN GALLATE - Use of (−)-epigallocatechin gallate and/or one or more of its derivatives for increasing the desire, willingness and/or motivation of animals (including humans), especially mammals, to exercise, to perform and/or to run, especially to perform endurance exercise and furthermore to accelerate training success.05-06-2010
20100035979Compositions and Methods of Sensitizing Methicillin Resistant Staphylococcus Aureus to Oxacillin - Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.02-11-2010
20100113585COMPOSITIONS AND METHODS FOR TREATING CANCER - Compounds of formulas I-IV: (I), (II), (III) (IV), wherein: R05-06-2010
20110201680 FORMULATION OF SILYMARIN WITH HIGH EFFICACY AND PROLONGED ACTION AND THE PREPARATION METHOD THEREOF - A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.94 times longer; when tested in vivo in Beagle dogs, this new formulation of silymarin presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method.08-18-2011
20110201679Use of Tocotrienols for Elevating IKBKAP Gene Expression and Treating Neurodegenerative Diseases or Disorders - The present invention provides methods for elevating IKBKAP gene expression and the level of functional IKAP protein in cells, which are beneficial to human individual, such as an individual suffering from a neurodegenerative disease or disorder such as Familial Dysautonomia, by providing one or more tocotrienols alone or in combination with one or more tocopherols to the cells. The present invention also provides methods for treating neurodegenerative diseases or disorders by providing tocotrienols alone or in combination with one or more tocopherols to a patient having a neurodegenerative disease such as Alzheimer's disease, Huntington's disease, amylotrophic lateral sclerosis as well as age-related cognitive decline. Related therapeutic kits are also provided.08-18-2011
20090197942Method For Producing Polyphenol-Rich Composition - An object of the present invention is to provide a method for producing polyphenol-containing compositions and purifying polyphenols safely and simply. By contacting a polyphenol-containing solution to a specific polysaccharide to support polyphenols with the polysaccharide, a polyphenol-containing composition usable as an additive for foods and drinks can be obtained. In addition, polyphenol can be purified by contacting polysaccharide-supported polyphenols with solvent to elute polyphenols into the solvent and then powderizing the polyphenols after removing the solvent.08-06-2009
20110263698PROANTHOCYANIDIN OF CASHEW APPLE, COMPOSITION CONTAINING PROANTHOCYANIDIN, AND APPLICATION THEREOF - This invention provides useful applications of cashew apple. This invention also provides a naturally occurring active ingredient having useful activities, such as alpha-amylase inhibitory activity, lipase inhibitory activity, and antibacterial activity against 10-27-2011
20080319051LIQUIRITIGENIN AND DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS - The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.12-25-2008
20100249224Methods and compositions for modulating glutamate dehydrogenase - Compositions, compounds, and methods for modulating the activity of glutamate dehydrogenase are disclosed. In addition, compositions, compounds, and methods for regulating insulin secretion and treating hyperinsulism/hyperammonemia and/or diabetes are disclosed.09-30-2010
20120035253CRYSTALLINE FORMS OF GENISTEIN - The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt.02-09-2012
20100184850PHENOLIC EXTRACTS OF ALMOND PEEL CONTAINING PROCYANIDINS, PROPELARGONIDINS, AND PRODELPHINIDINS, AND METHOD FOR PREPARATION THEREOF - The present disclosure concerns phenolic extracts containing procyanidins, propelargonidins and prodelfinidins obtained from peel of the almond [07-22-2010
20110021619EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE - To increase a tissue regeneration ability of a living body such as a collagens production ability of fibroblast in the dermis in a skin defect area typified by a large wrinkle or wound, a flavanone derivative such as farrerol is used as an active ingredient of an external preparation for skin. Further, to efficiently screen a substance having an excellent effect on promoting wound healing, the remodeling action of collagen fiber bundle is tested by using skin wound model.01-27-2011
20100099755CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF - Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.04-22-2010
20120232135(-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:09-13-2012
20090281174SENESCENCE INHIBITOR - Provision of a drug, a quasi-drug, and a food or beverage, which are effective for senescence inhibition, mitochondrial function improvement, muscle dysfunction inhibition, muscular atrophy inhibition, prevention of a bedridden state, muscle senescence inhibition, or motor function improvement. A senescence inhibitor, a mitochondrial function-improving agent, a muscle dysfunction inhibitor, a muscular atrophy inhibitor, and an agent for preventing a bedridden state, containing a catechin as an effective ingredient. A muscle senescence inhibitor and a motor function-improving agent, containing a catechin and an amino acid as effective ingredients.11-12-2009
20090270495Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof - We disclose substances and a process of developing such substances as potent and selective inhibitors of isoforms of phosphodiesterases of types 1 to 5 (PDE1, PDE2, PDE3, PDE4, PDE5) based on two flavonoids: dioclein, floranol and natural or synthetic analogs thereof. They may be associated with cyclodextrins in inclusion complexes or using a biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof in controlled release devices. Their respective pharmaceutical compositions as well as pharmaceutical and pharmacologically acceptable excipients may be used for the study and treatment of cardiovascular diseases and associated products.10-29-2009
20110172300NOVEL EPIGALLOCATECHIN GALLATE TRIMER AND ALPHA-GLUCOSIDASE INHIBITOR CONTAINING EPIGALLOCATECHIN GALLATE POLYMER - The present invention provides an α-glucosidase inhibitor containing a novel epigallocatechin gallate trimer and an epigallocatechin gallate polymer. Decomposition of starch derived from a meal and sugar derived from a polysaccharide can be suppressed by α-glucosidase inhibitory action, thus suppressing absorption. A food and drink excellent in α-glucosidase inhibitory action for suppressing sugar absorption and further for preventing diabetes for a long time can be provided by adding the α-glucosidase inhibitor to a food and drink.07-14-2011
20090170929Composition for the Protection and Preservation of Organs, Tissues or Cells and the Use Thereof - The present invention provides a composition for efficiently protecting and preserving organs, tissues or cells. In particular, the present invention provides a protective composition which can be used during operations. Specifically, the present invention provides a composition for protecting and preserving organs, tissues or cells, comprising a polyphenol. A method is also provided for protecting an organ, tissue or cell in a subject, comprising 1) exposing the organ, tissue or cell to a polyphenol. Such a composition and a polyphenol is effective in protecting a function of an organ (particularly, the heart, brain, nerve, spinal cord and the like).07-02-2009
20110207807NEW USE FOR HOMOISOFLAVONE OR A SALT THEREOF - The present disclosure relates to a new use of homoisoflavanone or a salt thereof. More particularly, it relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases or allergic diseases comprising homoisoflavanone represented by Chemical Formula 1 or a salt thereof, a use of homoisoflavanone or a salt thereof in the manufacture of an agent for the preventing and treating of inflammatory diseases or allergic diseases, and a method for treating inflammatory diseases or allergic diseases including administering an effective dose of homoisoflavanone or a salt thereof to a subject in need thereof.08-25-2011
20080275109NEUTRALIZING AGENT FOR VACUOLATING TOXIN - A drug, quasi drug, food or drink product containing a proanthocyanidine derived from hop, hop bract or apple has the effect of neutralizing or attenuating a vacuolacting toxin produced by 11-06-2008
20110207806FORMULATION OF DUAL CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX) INHIBITORS FOR MAMMAL SKIN CARE - The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in normal, aged and damaged dermal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the skin mediated by cyclooxygenase (COX) and lipoxygenase (LOX). The method for preventing and treating COX and LOX mediated diseases and conditions of the skin is comprised of topically administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the 08-25-2011
20080287528THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES - Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R11-20-2008
20080306141Method of Extraction of Catechin Type-A Proanthocyanidins - Catechin type-A proanthocyanidins are recovered from cinnamon bark or other sources rich in catechin type-A proanthocyanidins by extraction with a first organic solvent to provide an extract rich in catechin type-A proanthocyanidins. This extract is combined with water and the organic solvent is removed by distillation so that proanthocyanidins are transferred to the aqueous phase with the precipitation of hydrophobic materials. The aqueous extract is further purified by contact with a second organic solvent that is immiscible with water and appropriate polarity to remove reddish colored, higher polymeric proanthocyanidins from the aqueous phase. The purified aqueous extract is then subjected to evaporative concentration to produce a first solid extract. Extraction of the first solid extract with dry acetone produces an organic extract which, upon removal of the acetone, produces a solid which is enriched in catechin type-A proanthocyanidins. Purity is increased by about another 20%. This purified extract is water-soluble and is free, or essentially free, of typical cinnamon aroma compounds.12-11-2008
20080306142Isolation, purification and synthesis of procyanidin B2 and uses thereof - Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus 12-11-2008
20080312316Chromone Derivatives Useful as Antagonists of Vr1 Receptors - The invention relates to novel heterocyclic compounds of the formula12-18-2008
20090312408ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS - Disclosed is the use of isoflavan and isoflav-3-ene compounds for the treatment of pathological conditions associated with or dependent on enhanced or abnormal angiogenesis in a mammal.12-17-2009
20090312407Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies - A compound, pharmaceutical composition and method for the treatment of mammals wherein the active therapeutic agent is a compound having the structure:12-17-2009
20080255226STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc.10-16-2008
20080227853ANDROGENE MEMBRANE RECEPTOR AGONIST - Disclosed is a method of treating or preventing a disorder influenced by the action of a membrane androgen receptor, wherein a patient suffering or expected of suffering of such disorder is administered in pharmaceutically effective amounts an agonist of the membrane androgen receptor, said agonist being selected among the group consisting of natural, unnatural, oligorimerised or rearranged catechin, epicatechin, and derivatives thereof. The disease being treated or prevented may be cancer.09-18-2008
20090264518LIQUID KOJI AND QUICK-BREWED MISO-LIKE FOOD - The present invention provides a method for producing a salt-free miso-like food having strong umami and rich flavor with strong taste. As a means to solve the problem, a liquid koji is prepared by culturing an 10-22-2009
20090264519INSULIN SENSITIVITY IMPROVING AGENT - The present invention relates to an insulin sensitivity-improving agent for obese children, which contains a catechin as an active ingredient. There is provided an insulin sensitivity-improving agent for obese children.10-22-2009
20100137425INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS - The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.06-03-2010
20100137423ANTIOXIDATIVE COMPOSITION CONTAINING ACACIA BARK DERIVATIVE - It is intended to provide a composition which is useful in preventing or treating tumor. Namely, a composition for preventing and/or treating tumor which is characterized by containing a component originating in the bark of a tree belonging to the genus 06-03-2010
20110207808LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS - Provided are long-chain carboxychromanol compounds useful for treating conditions associated with the need to inhibit cyclooxygenase-1, cyclooxygenase-2, and/or 5-lipoxygenase, and pharmaceutical formulations containing the compounds.08-25-2011
20090163578NOVEL MODIFICATION OF IMMUNOMODULATORY PROTEIN - Methods of inhibiting annexin I induced apoptosis by contacting a cell population containing a TRPM7/ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase.06-25-2009
20090163580Anti-aging composition containing resveratrol and method of administration - Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.06-25-2009
20120071550Synergistic combinations of cartonoids and polyphenols - The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE03-22-2012
20090118357Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field - Therefore the present invention relates specifically to the compounds of general formula (I), in which R05-07-2009
20090281173COMPOSITIONS CONTAINING RETINOID AND CHROMENONE DERIVATIVES - The present invention relates to a composition including at least one retinoid and at least one chromenone derivative and the use thereof for the preparation of a cosmetic article to be used for the topical application to skin, hair or nails.11-12-2009
20090186936TEA BEVERAGES CONTAINING PROANTHOCYANIDINS - The object is to provide beverages that allow for sustained intake and which have an effect of improving the vascular endothelial function as by promoting the secretion of NO from vascular endothelial cells so as to potentiate the NO action.07-23-2009
20090186937Method for Treating Addiction Using Quercetin-Containing Compositions - This invention relates to a method of treating addiction using a composition containing quercetin. Preferably, it also contains vitamin B07-23-2009
20090118358Kainate Receptor-Selective Epimeric Analogs of Dysiherbaine - Disclosed are compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a GluR5 receptor, a GluR6 receptor, or both receptors. The pharmaceutical compositions include and the methods utilize compounds that are analogs and stereoisomers of dysiherbaine and neodysiherbaine which have specificity for kainate receptors.05-07-2009
20100004325Use of Baicalein As Prolyl Hydroxylase 2 Inhibitor - The present invention is to prove a new molecular and cellular effect of baicalein, which is selected by a prolyl hydroxylase 2 (PHD2) inhibitor screening method using a compound library. Specifically, the present invention quantitatively analyzed the inhibitory effect of the baicalein against PHD2, confirmed the inhibitory effect against FIH (factor inhibiting HIF), analyzed the HIF (hypoxia inducible factor) protein expression induced by baicalein in a cell, and then, confirmed whether the VEGF is expressed by using reporter assay and ELISA. The above effect of baicalein proves that it can be used for a drug treating ischemic diseases, and, therefore, it can be used for other related diseases.01-07-2010
20080319050Preparation Containing Oxidized Flavonoid Derivatives - The invention relates to novel compositions, in particular cosmetic and/or pharmaceutical compositions or food supplements, comprising at least one oxidised flavonoid derivative of the formula I, to novel oxidised flavonoid derivatives, and to novel uses of the oxidised flavonoid derivatives.12-25-2008
20080319052Lipopexia Inhibitor and Food or Beverage - [Problems] To provide a lipopexia inhibitor being effective for the inhibition of fat accumulation.12-25-2008
20080319053Anthocyanin pigment/dye compositions through corn extraction - Anthocyanin pigments/dyes are extracted from corn kernels by adding corn kernels with less than 5% by weight of corn kernels comprising broken kernels to an aqueous medium to form an aqueous-corn medium. The corn kernels have in excess of 0.1 mg of anthocyanin pigment/dye per gram of corn kernel therein. The anthocyanin pigment/dye in the corn kernels has greater than 40% by weight of anthocyanin as an acid or acylated form of the anthocyanin. The aqueous corn medium is agitated at a temperature above 35° C. The solid corn kernels are separated from the aqueous corn medium to form an extract of anthocyanin in aqueous medium having less than 1.0% solids therein before concentration or purification steps are performed on the extract.12-25-2008
20090326056NOVEL ACTIVES AGAINST PROSTATE CARCINOMA - The present invention relates to the use of a composition comprising lycopene and genistein in the prevention and coadjuvant treatment of prostate carcinoma. The present invention is also directed to the use of a composition comprising lycopene and epigallocatechin gallate in the prevention and coadjuvant treatment of prostate carcinoma. More specifically, the present invention relates to the use of one of these compositions in the primary prevention (i.e., the prophylactic supplementation of healthy subjects) of the onset of prostate carcinoma, in the coadjuvant treatment (i.e. the supplementation accompanying a running therapy of prostate carcinoma) and in the secondary prevention (i.e., the supplementation after a successful therapy for the prevention of relapse) of prostate carcinoma. Furthermore, the present invention is also directed to the reduction/decrease of the PSA plasma level in the blood of subjects to whom either a composition comprising lycopene and genistein or to whom either a composition comprising lycopene and epigallocatechin gallate are administered. Further compounds that may preferably also be present in the composition of the present invention are vitamin E, resveratrol and polyunsaturated fatty acid (derivative)s.12-31-2009
20090326055Chroman-Derived Compounds For The Treatment Of Cancer - The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.12-31-2009
20090036518PHARMACEUTICAL COMPOSITION CONTAINING FLAVONOIDS - A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess (PDE4), as a main ingredient. Especially, this composition has a binding affinity of high affinity rolipram binding sites (HARBS) of a PDE4 lower than a binding affinity of low affinity rolipram binding sites (LARBS) of the PDE4 is used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), or chronic inflammation, and has bronchodilatory effects. In addition, whether the above-mentioned flavonoids have side effects, such as nausea, vomiting, gastric hypersecretion, etc., in accordance with their binding affinity to HARBS of particulates of brain cells are disclosed.02-05-2009
20110224291SKIN EXTERNAL COMPOSITION FOR INHIBITING EPIDERMAL HYPERPROLIFERATION AND ALLEVIATING INFLAMMATORY SKIN DISEASES CONTAINING ORTHODIHYDROXYISOFLAVONE DERIVATIVES - Disclosed herein is a skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases, which contains ortho-dihydroxyisoflavone derivatives as an active ingredient. Specifically, the skin external external composition contains the ortho-dihydroxyisoflavone derivatives, 4′,6,7-trihydroxyisoflavone, 3′,4′,7-trihydroxyisoflavone or a mixture thereof, and thus increases the expression of DKK3 protein and FZD1 protein, which appropriately control Wnt signaling, thereby inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases caused by epidermal hyperproliferation.09-15-2011
20110224290COMBINE USE OF PTEROSTILBENE AND QUERCETIN FOR THE PRODUCTION OF CANCER TREATMENT MEDICAMENTS - The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 μM)+QUER (20 μM) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg×day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.09-15-2011
20090023803Use of cacao polyphenols for treating a prostate hyperplasia, a specific cacao extract and applications - The invention relates to the use of cacao polyphenols for preventing or curing a prostate hyperplasia, to a cacao polyphenol extract which also comprises, in particular lipids and/or xanthines, and to the applications of said extract in food and pharmaceutical products for treating a prostate cancer, cognitive disorders, oxidative stress and cholesterol.01-22-2009
20090023804ELECTROCHEMICAL METHODS FOR REDOX CONTROL TO PRESERVE, STABILIZE AND ACTIVATE COMPOUNDS - To maximize and maintain the antioxidant or pro-oxidant state for foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations or drags, the present invention discloses methods and devices to control redox equilibrium of such preparations throughout the processing steps and storage prior to, or at, the time of administration or use. The preparations (solid or liquid form) can then be stored in a redox-controlled container, package or applicator as described in the specification. Foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations and drugs stored in reactive oxidation states can be activated and stabilized by electrical voltages applied with a small battery and electrodes designed into the applicator, container or package.01-22-2009
20090197944AGENT FOR IMPROVING MUSCLE FORCE - Provision of an agent for improving muscle force and for improving exercise effect. An agent for improving muscle force containing a catechin as an effective ingredient.08-06-2009
20090062379COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS - Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease.03-05-2009
20090054518AMPelopsin Unsaturated Sodium Salt Preparation and Applications thereof - A ampelopsin salt, its derivatives preparation and application are new. The ampelopsin salt being formed by substituting a monovalent cation for hydrogen atom on the ampelopsin, and the said substitution is a unsaturated substitution, is prepared by the reaction of ampelopsin with salify agent, and which is used for preparing antitumour medicine, and combined with other antitumour medicine thus reduce side effect of other antitumour medicine.02-26-2009
20090082428SPIROKETALS - The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.03-26-2009
20090062380ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their semisynthetic derivatives are represented by formula (I), in which R03-05-2009
20120035254INHIBITOR FOR ELEVATION OF GIP LEVEL - Provided is a GIP-increase inhibitor, which is customary used for food production, is excellent in safety, and is useful for, for example, a medicine or a food. The GIP-increase inhibitor contains catechins as active ingredient.02-09-2012
20110230550COMPOUNDS, COMPOSITIONS AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.09-22-2011
20080262080Allergy Suppressive Agent - The present invention provides a novel agent/composition using a bioregulatory function of a food ingredient.10-23-2008
20090221694Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone - Compositions comprising epigallocatechin gallate and 4-(4-hydroxyphenyl)-2-butanone may be used for treatment or prevention of obesity or conditions associated with obesity such as non-insulin-dependent diabetes mellitus (NIDDM, type II) and syndrome X. The compositions may find use in the nutritional field as a supplement to food and beverages, as well as a pharmaceutical formulation.09-03-2009
20120077875COMPOSITION INCLUDING AT LEAST ONE TRANS-CINNAMALDEHYDE AND THE USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS, SPECIFICALLY IN THE TREATMENT OF NOSOCOMIAL INFECTIONS - The present invention relates to a composition, in particular an antibacterial drug, including trans-cinnamaldehyde, a pharmaceutical composition including trans-cinnamaldehyde for treatment or prevention, in particular, of a nosocomial infection, specifically caused by a bacteria resistant to anti-bacterial drugs, the use of trans-cinnamaldehyde as an anti-bacterial agent and a method for preparing a surface including the application of a composition according to the invention.03-29-2012
20120077874DEVELOPMENT OF A PHYTOESTROGEN PRODUCT FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS USING RED CLOVER - A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage ranges from 5 to 200 mg of total isoflavone.03-29-2012
20120077873Methods of Reducing Blood Lactate Concentration - The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.03-29-2012
20090209635TOPICAL CROMOLYN FORMULATIONS - The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.08-20-2009
20090209636Novel use of (-)-epigallocatechin gallate - An apparatus for generating a data stream having a series of segments using data organized in subsequent data frames, a data frame having more important and less important data. It comprises a packetiser for packetising data from a data frame into the series of segments having a first segment and a second segment, where the packetiser is operative to packetise the data of the frame so that a starting point of the more important data coincides with a starting point of the first segment and an information block adder for adding a first information block to the first segment.08-20-2009
20090209637USE OF CHROMEN-4-ONE DERIVATIVES - The invention relates to the use of chromen-4-one derivatives of the formula I08-20-2009
20090221696COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD FOR THE SAME - A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells.09-03-2009
20090258941USE OF FUSAROCHROMANONE AND ITS DERIVATIVES IN THE DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES - A method of photodynamic therapy to treat diseased cells in an animal is generally provided. According to the method, 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is administered to the animal such that the 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof accumulates in the diseased cells. Then, the diseased cells containing 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is exposed to light energy (e.g., ultraviolet light).10-15-2009
20090239943Nutraceutical composition and methods for its use - A composition for inhibiting the activity of NF kappa B or for inhibiting tissue damage inflammation due to disease including a combination of green tea polyphenols; resveratrol; soy isoflavones, and curcumin. Also disclosed is a method of inhibiting the activity at the NF kappa B or inflammation using the composition.09-24-2009
20120035252POLYPHENOL-RICH EXTRACT FROM PLANT MATERIAL - A process is provided for preparing (1) a first composition obtained by extracting a plant material with a single phase mixture of water and at least a first organic solvent under agitation so as to obtain a first extract rich in polyphenol oligomers, wherein the first composition is the first extract, and (2) a second composition obtained by extracting at least a portion of the first extract with a biphasic mixture of water and at least a second organic solvent under agitation so as to obtain a second extract rich in polyphenol monomers, dimers, and trimers, wherein the second composition is the second extract. Food products, mendicants, and cosmetics containing the first composition or the second composition are also provided.02-09-2012
20100273869ANTI-CANCER TOCOTRIENOL ANALOGUES AND ASSOCIATED METHODS - Compounds are disclosed relating to the treatment of cancer that include tocotrienols and derivatives of tocotrienols including 2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-ylphenylsulfonylcarbamate; (R)-2,8-dimethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yl tosylcarbamate; and (R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yl benzylcarbamate. Therapeutic uses of these types of compounds are also taught.10-28-2010
20090258939PYRONE ANALOG COMPOSITIONS AND METHODS - Novel pyrone analogs are described which can enhance the effectiveness of a therapeutic agent when administered and/or reduce side effects caused by the administration of a therapeutic agent.10-15-2009
20100160427METHOD OF TREATING VASCULAR INJURIES INDUCED BY AN EXCESS OF PLASMA LIPIDS USING COMBINATIONS OF VASOPROTECTIVE AGENTS - Combinations of vasoprotective agents useful for the prevention and the treatment of vascular injuries induced by an excess of plasma lipids comprising polycosanols, tocotriends and/or lycopene, procyanidole oligomers and vegetable oil rich in insaturated fatty acids.06-24-2010
20100152285Flavononol Renin Inhibitor Compounds and Methods of Use Thereof - The present disclosure relates in part to methods of treating or preventing renin mediated conditions comprising administering to a subject in need thereof a flavononol compound represented by formula I:06-17-2010
20100152284PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - Provided herein are methods for treating or preventing neuropathy, neuropathy-related conditions, wherein the neuropathy or neuropathy-related conditions are induced by, or otherwise associated with, treatment of the subject with at least one chemotherapeutic agent, the methods comprising administering an effective amount of an isoflavonoid compound of formula (I). Also provided are methods for the treatment of nerve damage. Also provided are uses of isoflavonoid compounds of formula (I) in the treatment of neuropathy, neuropathy-related conditions and nerve damage.06-17-2010
20100261784AGENT FOR REDUCING INTESTINAL TOXIC BACTERIUM AND FOOD OR PHARMACEUTICAL PREPARATION COMPRISING THE SAME - An agent for reducing an intestinal toxic bacterium is provided, the agent including: a pulverized product or extract of a plant of the genus 10-14-2010
20100190846MICROBICIDAL AGENT AND MICROBICIDAL COMPOSITION - A method for suppressing the growth of microorganism comprises the steps of providing a microbicidal agent comprising 5,7,4′-trihydroxy-3′,5′-dimethoxyflavone, and contacting the agent with the microorganism, wherein said microorganism is selected from the group consisting of 07-29-2010
20100197778PROANTHOCYANIDINS FOR THE TREATMENT OF AMYLOID AND ALPHA-SYNUCLEIN DISEASES - A method of treating an amyloid disease, or a disease characterized by IAPP amyloid fibrils or islet amyloid deposits, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed procyanidins or proanthocyanidins characterized by disclosed general formulae. A pharmaceutical composition and use of the composition comprising a therapeutically effective amount of a procyanidin and a pharmaceutically acceptable excipient. The therapeutic amount of the proanthocyanidin is selected for efficacy in treating IAPP amyloid fibrils or islet amyloid deposits in a mammalian subject.08-05-2010
20100190844PROCESS FOR PREPARATION OF AGLUCONE ISOFLAVONES - The present invention provides a process for producing a composition containing a high concentration of aglucone isoflavones, which comprises adding glucone isoflavones to the fermentation of microorganisms which are generally recognized as safe, and can express or produce β-glycosidase on a soy-based substrate. The present invention also provides a composition containing a high concentration of aglucone isoflavones produced in accordance with the process of the invention.07-29-2010
20110060039COMPOSITION - A cocoa powder having a polyphenol content of at least 5% by weight, may be used to provide skin benefits by oral administration. Preferably, the cocoa powder is provided as part of a foodstuff or confectionary product, or as a cosmetic composition or supplement, The skin benefit preferably comprises a reduction in the degree of wrinkling of the skin and/or an improvement in the smoothness of the skin.03-10-2011
20110060038NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF - This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.03-10-2011
20090170928Synthesis of oligo/poly(catechins) and methods of use - A method for synthesizing a biocompatible, water-soluble oligo/polyflavanoid, includes polymerizing an optionally substituted flavanoid with a polymerization agent in the presence of a biocompatible polymerization solubilizer, thereby producing the biocompatible, soluble oligo/polyflavanoid. Also included is a biocompatible, soluble, oligo/polyflavanoid or a pharmaceutically acceptable salt, solvate, or complex thereof. Also included are methods of treating a subject for cancer, cardiac damage, viral infection, and obesity.07-02-2009
20090149530Antiinfective Flavonol Compounds and Methods of Use Thereof - In one aspect of the invention, the antiinfective agents are flavonol compounds of the represented by formula I:06-11-2009
20100144860Transglutaminase Inhibitor Comprising EGCG And A Method For Producing Thereof - The present invention relates to a transglutaminase inhibitor comprising epigallocatechin gallate (hereinafter, referred to as EGCG). More particularly, the present invention relates to a transglutaminase inhibitor comprising EGCG which effectively inhibits the activity of transglutaminase, the overexpression of which is responsible for the etiology of various diseases, and to novel uses thereof. According to the present invention, provided is a transglutaminase inhibitor and a method of inhibiting transglutaminase, featuring the use of EGCG as an active ingredient. Featuring the use of EGCG, the novel method of inhibiting transglutaminase according to the present invention is safely applied to patients who suffer from the diseases caused by the overexpression of transglutaminase, thereby obtaining an inhibitory effect against transglutaminase without casuing side-effects.06-10-2010
20100144858Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator - An mGluR4 receptor positive allosteric modulator is useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders such as Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonian, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia.06-10-2010
20100160425ANTI-ALLERGIC AGENT AND BEVERAGE/FOOD, PREPARATION FOR EXTERNAL APPLICATION OR COSMETIC COMPRISING THE AGENT - The object is to isolate a substance having a potent anti-allergic effect inherent in tea leaves of an Assam hybrid line. Thus, disclosed is an anti-allergic agent comprising, as an active ingredient, a catechin yielded by the isolation, i.e. epicatechin-3-O-(3-O-methyl)gallate, epicatechin-3-O-(4-O-methyl)gallate, epicatechin-3-O-(3,4-O-dimethyl)gallate, epicatechin-3-O-(3,5-O-dimethyl)gallate, epicatechin-3-O-(3,4,5-O-tromethyl)gallate, an epimer thereof or the like. Also disclosed is a food/beverage, a preparation for external application, and a cosmetic including the anti-allergic agent. An anti-allergic composition can be prepared using a compound represented by the general formula (1):06-24-2010
20110112184COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION - Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X=—CH05-12-2011
20100144859DIMERIC AVERMECTIN AND MILBEMYCIN DERIVATIVES - This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections and infestations in animals or for combating pests in plants or plant propagation material.06-10-2010
20100144856PRENYLFAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.06-10-2010
20120196927PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR METABOLIC SYNDROME - A method for screening a substance for treating visceral adiposity syndrome comprises: (1) extracting a total RNA fraction from skeletal muscle collected from non-human mammals of a group to which a predetermined amount of the test substance has been administered and from non-human mammals of a group to which the test substance has not been administered; (2) quantifying the expression quantity of mRNA in the total RNA fraction extracted that encodes a glucose transporter gene by a specific method; and (3) comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the glucose transporter gene during the administration period for the non-human mammals of the test substance-administered group to these quantities for the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.08-02-2012
20110112183Oligomer-Bis-Chromonyl Compound Conjugates - The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.05-12-2011
20100222423ASPALATHIN-LIKE DIHYDROCHALCONE, EXTRACTS FROM UNFERMENTED ROOIBOS AND PROCESS FOR PREPARATION - The present invention relates to a novel chemical compound of the formula I and to the pharmaceutically acceptable salts, derivatives and esters thereof. In addition, the invention also relates to a process for isolating the compound according to formula I from raw rooibos material. The present invention likewise relates to a rooibos extract which has a content of the compound according to formula I of at least 0.4% by weight. The invention furthermore relates to the use of the chemical compound of the formula I and of the pharmaceutically acceptable salts, derivatives and esters thereof and of the rooibos extract according to the invention as a medicament, in particular for treating neurological and psychiatric disorders of the central nervous system. The expression “pharmaceutically active” also includes those effects which lead to a subjective improvement in the mental state, in which case approval under pharmaceutical legislation need not be absolutely necessary. Compound of the formula I is shown below:09-02-2010
20100222421Usage of Baicalein in the Preparation of a Pharmaceutical Composition for the Treatment of Traumatic Brain Injury - The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or carrier. The baicalein pharmaceutical composition is applicable for improving the behaviour function deficit in traumatic brain injury, reducing the contusion volume of traumatic brain injury, improving the brain neuronal degeneration in traumatic brain injury, reducing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) or other relative inflammation factor induced in traumatic brain injury.09-02-2010
20100120904NOVEL USE OF GENISTEIN - Use of genistein for the treatment and prevention of dry eye syndrome or LKC and corresponding compositions containing it.05-13-2010
20110028540SYNTHESIS OF MACROCYCLIC CANCER CHEMOTHERAPY AGENTS AND METHODS OF USE - Herein are described a process for forming a quaternary carbon useful in the preparation of macrolactones, an enantioselective synthesis of (+)-peloruside A, and methods for treating a patient in need of relief from cancer or a cancer-related disease. The described processes are useful for preparing compounds containing quaternary carbons, including structural analogs and derivatives of peloruside A.02-03-2011
20090318545Mast cell inhibition in diseases of the retina and vitreous - This application discloses methods for treating or preventing an ophthalmic retinal vascular permeability, angiogenic or fibroproliferative disease, disorder or condition that involve administering to a patient in need thereof a composition that can inhibit mast cell migration into the vitreous or the retina, mast cell proliferation in the vitreous or the retina, or mast cell secretion into the vitreous or the retina.12-24-2009
20090111868Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders - The present invention provides compositions and methods for regulating the BK channel using rottlerin and derivatives thereof. In particular, the present invention provides pharmaceutical compositions for use in treating or preventing BK channel medicated disorders including hypertension and various hyperexcitability disorders. Also provided are compositions and methods for use in post-stroke neuroprotection and in treating or preventing erectile dysfunction. The present invention further provides kits for use in treating or preventing BK channel mediated disorders, comprising the compositions of the present invention.04-30-2009
20090069415DEUTERIUM-ENRICHED NEBIVOLOL - The present application describes deuterium-enriched nebivolol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20120142767PINE PCO ESTER COSMETIC COMPOSITION - The invention relates to a cosmetic composition for repairing and optionally preventing the effects of skin ageing, based on an extract of 06-07-2012
20100298424METHOD FOR TREATING ABDOMINAL DISCOMFORT - Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders.11-25-2010
20130131158ANTIVIRAL COMPOSITION - The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs.05-23-2013
20130131160NEW USE OF HESPERETIN - The present invention discloses a use of hesperetin or a hesperetin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of hesperetin or a hesperetin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using hesperetin. The skin microcirculation of the present invention is preferably eye skin microcirculation.05-23-2013
20130137761NEW COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF OSTEOARTHROSIS - The present invention relates to new compounds which are inter alia derivable from hops for use in the treatment of (for treating)/prevention or healing of a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage (and/or for the prevention of aggrecan loss). Food products comprising these compounds for use in the treatment (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer, in particular a disease which is associated with or characterized by degeneration and/or a destruction of cartilage, are also envisaged.05-30-2013
20130137762COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASE OR NEUROPATHOLOGICAL CONDITION - This invention relates to extracts and refined fractions of a traditional Chinese medicinal herb, 05-30-2013
20130143957POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF - There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.06-06-2013
20130143958DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in a range of about 6-96 μg:06-06-2013
20100331400CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS - The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).12-30-2010
20110009481MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES - The invention relates to a medicament containing a compound of general formula (I), where R01-13-2011
20110245334USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE - Use of a racemate of pinocembrin, a racemate of pinocembrin salt, a racemate of pinocembrin precursor or a racemate of pinocembrin hydrate in manufacture of a medicament for prophylaxis and treatment of stroke. Particularly, use of pinocembrin racemate in manufacture of a medicament for treatment of acute ischemic stroke.10-06-2011
20110245333IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS - The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier.10-06-2011
20110034548Method for Suspending a Flavonoid in a Beverage - Disclosed is a method for suspending microparticulated flavonoid in a beverage by incorporating a microparticulated flavonoid and at least one suspension agent into a beverage. A composition comprising microparticulated quercetin and a suspension agent is also disclosed.02-10-2011
20110118345COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS - A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.05-19-2011
20090221695Chroman Derivatives as Estrogenic Compounds - The invention provides chroman compounds having formula 109-03-2009
20110130447Production of hop extracts having oestrogenic and antiproliferative bioactivity - A method for the production of a hop extract which is enriched in 8-prenylnaringenin with respect to 6-prenylnaringenin include the steps of subjecting a hop product to (1) an isomerisation reaction in the presence of water as a solvent and in the presence of an amount of a base and (2) to at least one extraction. In that way a hop extract is obtained which contains 6-prenylnaringenin and 8-prenylnaringenin in a ratio (8-prenylnaringenin×100%)/(8-prenylnaringenin+6-prenylnaringenin) of at least 50%. The extract preferably also contains xanthohumol, the weight ratio of xanthohumol to 8-prenylnaringenin being at least 10.06-02-2011
20110124722COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA USING ORTANIQUE PEEL EXTRACT - The invention relates to compositions and methods for treating hypercholesterolemia, including methods for increasing HDL cholesterol levels, using a composition comprising an extract from the Ortanique peel. The invention also relates to compositions and methods for treating hypercholesterolemia, including methods for increasing HDL cholesterol levels, using a composition comprising substantially similar amounts of tetramethylscutellarein and nobiletin by weight and/or a composition comprising substantially similar amounts of tetramethylscutellarein, nobiletin, and tangeretin by weight.05-26-2011
20110124721METHODS OF TREATING TRAUMATIC BRAIN INJURY BY ADMINISTERING BAICALEIN PREPARATION - The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or carrier. The baicalein pharmaceutical composition is applicable for improving the behaviour function deficit in traumatic brain injury, reducing the contusion volume of traumatic brain injury, improving the brain neuronal degeneration in traumatic brain injury, reducing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) or other relative inflammation factor induced in traumatic brain injury.05-26-2011
20110124719COMPOSITION FOR PROMOTING PRODUCTION OF HYALURONIC ACID CONTAINING KAEMPFEROL AND QUERCETIN - Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin. Kaempferol and quercetin of the invention increase an expression of a hyaluronic acid synthase (HAS) gene existing in a skin cell line of human epidermis, thereby promoting a production of hyaluronic acid in the human cell. Accordingly, the composition containing at least one of kaempferol and quercetin according to the invention can be usefully used as a cosmetic composition for increasing skin elasticity and preventing skin dryness or aging, or a pharmaceutical composition for treating or preventing a degenerative arthritis.05-26-2011
20110124720COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS - Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (-)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease.05-26-2011
20100222424Method of Screening Drug with the Use of 67 kDa Laminin Receptor and Drug Obtained Thereby - It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step, of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, and angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic-effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.09-02-2010
20110178168COUMARIN COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND A PROCESS FOR PREPARING THE SAME - The present invention relates to compounds of Formula (I): wherein—X and Y represent O, S, NR′; R07-21-2011
20090312409LIPOPEXIA INHIBITOR AND FOOD OR BEVERAGE - A lipopexia inhibitor which inhibits fat accumulation, comprising an effective amount of any methylated catechin having the following chemical formula (1) obtained by extraction of green tea or Pouchung tea, in which each of R12-17-2009
20100016420Composition for the Treatment of Resistant Cancers Comprising Oridonin - The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be used in relatively low amounts for the treatment of stage IV or recurrent cancer which may have grown resistant to the traditional chemotherapeutic agents. These compositions comprise oridonin.01-21-2010
20100056619Chroman-Derived Anti-Androgens For Treatment of Androgen-Mediated Disorders - Methods for the prevention and/or alleviation of androgen-mediated disorders by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.03-04-2010
20100069477METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME - The invention provides a methioninase inhibitor to suppress the production of methyl mercaptan that is a causative substance of a bad smell by inhibiting methioninase originated from bacteria, as well as a composition and a food or drink containing the same, wherein the methioninase inhibitor contains an extract obtained from a plant of the family 03-18-2010
20100056618DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES - Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).03-04-2010
20100069478ISOFLAVONE DERIVATIVES AND USES THEREOF - Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning.03-18-2010
20100069480METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Isolated compounds and combinations of isolated compounds isolated from 03-18-2010
20100069479NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION - The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated neurodegenerative diseases. The neurodegenerative disease is treated using a JAK/STAT pathway inhibitor, including (—)-epigallocatechin-3-gallate (EGCG), to modulate JAK1 or STAT1 phosphorylation, resulting in resistance to gp120 or Tat neurotoxicity. The invention may be used to treat neurons afflicted with HIV-associated Dementia, multiple sclerosis, Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, or Pick's Disease, and may act in conjunction with antiviral treatment, like HAART.03-18-2010
20100069476COMPOSITIONS AND METHODS FOR REDUCTION OF CUTANEOUS PHOTOAGEING - Compositions and methods are provided in which a topical hydrophilic formulation includes a catechin and a hydrophilic antioxidant in a hydrophilic composition at a ratio of between 2.3 to 1.7 (by weight), ad wherein the catechin and the antioxidant are present in an amount such that application of the composition to skin will deposit the catechin at a dosage of between 0.7 mg/cm2 and 1.3 mg/cm2. Especially preferred catechins include green tea catechins, and particularly EGCG, while preferred antioxidants include ascorbic acid and derivatives thereof.03-18-2010
20110082197Method for inhibiting formation and/or activation of osteoclasts using flemingia macrophylla extract or lespedeza flavanone A - A method for inhibiting the formation and/or activation of osteoclasts in a mammal comprising administrating an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof to the mammal is provided:04-07-2011
20110082198THEAFLAVIN COMPOSITIONS, PRODUCTION, AND METHODS TO CONTROL PHYSIOLOGICAL DISORDERS IN MAMMALS - A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3. Methods of treatment of human physiological disorders are provided which comprise administering oral dosage forms of the compositions.04-07-2011
20090030070EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE - To increase a tissue regeneration ability of a living body such as a collagens production ability of fibroblast in the dermis in a skin defect area typified by a large wrinkle or wound, a flavanone derivative such as farrerol is used as an active ingredient of an external preparation for skin. Further, to efficiently screen a substance having an excellent effect on promoting wound healing, the remodeling action of collagen fiber bundle is tested by using skin wound model.01-29-2009
20110086909SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY - The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.04-14-2011
20110082196THEAFLAVIN COMPOSITIONS, RELATED PROCESSES AND METHODS OF USE - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form.04-07-2011
20120277302EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc.11-01-2012
20110251271COSMETIC COMPOSITION WITH ANTI-FREE RADICAL ACTIVITY - Cosmetic compositions with anti-free radical activity have been developed. Such compositions preferably contain an association of at least the following three substances with anti-free radical activity: idebenone; N-acetylcysteine, and alpha-tocotrienol or an ester thereof with a C10-13-2011
20130131159PLECTRANTHUS AMBOINICUS FRACTION HAVING ANTI-ARTHRITIS ACTIVITY - The invention provides an extract of 05-23-2013
20080249163Process For Producing Product Containing Proanthocyanidin in High Proportion - A proanthocyanidin-containing product containing a large amount of highly bioactive OPCs can be obtained easily by treating an extract or juice of a plant with at least two types of adsorbents that differ from one another in at least one of material, pore radius, specific surface area, and an ability of adsorbing and releasing a substance based on the molecular weight of the substance.10-09-2008
20110152361NOVEL EPIGALLOCATECHIN GALLATE TETRAMER AND VASCULAR ENDOTHELIAL FUNCTION IMPROVING AGENT CONTAINING THE SAME - Providing a compound capable of continuously taking and having a vascular endothelial function improving effect by enhancing NO function from the vascular endothelial cells.06-23-2011
20090258942CALYCOSIN AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES - Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.10-15-2009
20120277298FLAVANONES-CONTAINING FOOD COMPOSITIONS - The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of compositions for the improvement of bone and skin health.11-01-2012
20090118360Process for manufacturing leaf tea - Disclosed is a process comprising the steps of: expressing juice from fresh tea leaves thereby to produce leaf residue and tea juice wherein the amount of expressed juice is greater than 300 ml per kg of fresh tea leaves; subjecting the fresh tea leaves and/or the leaf residue to an enzyme deactivation treatment thereby to prevent fermentation of the leaf residue; and drying the leaf residue to produce leaf tea. Also disclosed is a leaf tea obtained by the process.05-07-2009
20090099256Drug for Treating Circulatory Insufficiency - The present invention relate to a drug for treating circulatory insufficiency containing a benzopyran derivative represented by the following general formula (I):04-16-2009
20110257258Method for Preventing and Treating Avian Influenza in Human - A method and composition for preventing and treating Avian Influenza in Humans utilizes an effective quantity of polyphenolic(s) and/or its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid, (−)-epigallocatechin gallate (EGCG), (−) epigallocatechin (EGC), (+)-epicatechin (EC), (−)-gallocatechin gallate (GCG), and catechin.10-20-2011
20110257259NUT SKIN PRODUCTS AND METHODS OF USE THEREOF - The invention relates to a method of treating or preventing a nitric oxide (NO)-responsive disease or disorder by administering to a subject in need thereof a composition, including foods such as confectionary and pet foods, comprising nut skins and/or a procyanidin-containing nut skins extract. Said composition may further comprise cocoa polyphenol(s) and/or L-arginine.10-20-2011
20080214659Stage-Specific Reduction of LUTS in Prostate Disease - Methods and compositions are presented in which catechin-containing compositions have statistically significant and strong therapeutic effect in the treatment of LUTS wherein such compositions are stage-specifically administered to a patient diagnosed with HG-PIN and optional coexistent BPH.09-04-2008
20080214658Composition Comprising Isoorientin for Suppressing Histamine - The present invention relates to a pharmaceutical composition for the prevention or treatment of diseases mediated by excessive histamine comprising naturally-derived isoorientin, a use of isoorientin for the manufacture of a medicament for the prevention or treatment of diseases mediated by excessive histamine, and a method for preventing or treating diseases mediated by excessive histamine comprising administering a therapeutically effective amount of isoorientin to a subject. The composition, use and method of the present invention show excellent histamine suppression effects, and so can be used for the prevention or treatment of various kinds of allergic disease, atopic disease, inflammatory disease, skin disease, hyperacidity and nervous system disorder.09-04-2008
20110021620USE OF TEA POLYPHENOLS IN PREPARING MEDICAMENTS FOR PREVENTION OR TREATMENT OF TUMORS - Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors is provided. The tea polyphenols are tea extracts comprising EGCG, EGC, and ECG, or Tegreen 97®, a green tea capsule of PHARMANEX, INC.01-27-2011
20110263696PROANTHOCYANIDINS FROM CINNAMON AND ITS WATER SOLUBLE EXTRACT INHIBIT TAU AGGREGATION - Compositions comprising proanthocyanidin compositions (e.g. those extracted from 10-27-2011
20110118344Novel compound having inhibitory effect on lipase - This invention provides, a novel polyphenol compound having lipase inhibitory activity derived from tealeaves, a process for the preparation of the compound, and foods and/or beverages and pharmaceutical drugs containing the compound.05-19-2011
20100305203METHOD FOR MODULATING CLAUDIN MEDIATED FUNCTIONS - Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above.12-02-2010
20100168220PLANT EXTRACT COMPOSITION FOR TREATING HEPATITIS C - The invention provides a plant extract composition for treating hepatitis C, including an effective amount of the proanthocyanidins oligomer extracted from a plant material, and a pharmaceutically acceptable carrier or salt, wherein the structure of proanthocyanidins is shown as follows:07-01-2010
20110136898TREATMENT OF RETINAL DEGENERATION - The use of a compound of general formula (I): or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells, wherein: R1 is a alkoxy, alkyl, ether or ester group; R2 is H or has the formula wherein Y is linear or branched, saturated or unsaturated, aliphatic group with from 2 to 23 carbon atoms, or a cyclic group, and which can contain substituents selected from the group consisting of hydroxyl, alkoxy, amino, carboxyl, cyano, nitro, alkylsuphonyl or halogen atoms, X is O or S; and R3 is any substituent.06-09-2011
20110082199USE OF NON-TOXIC CROSSLINKING REAGENTS TO IMPROVE FATIGUE RESISTANCE AND REDUCE MECHANICAL DEGRADATION OF INTERVERTEBRAL DISC AND OTHER COLLAGENOUS TISSUES - A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. The crosslinking reagent includes a crosslinking agent such as genipin and/or proanthrocyanidin. Further, the crosslinking reagent may include a crosslinking agent in a carrier medium. The collagenous tissue to be contacted with the crosslinking reagent is preferably a portion of an intervertebral disc or articular cartilage. The contact between the tissue and the crosslinking reagent is effected by injections directly into the select tissue using a needle. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system such as a gel or ointment, or a treated membrane or patch directly into or onto the target tissue. Contact may also be effected by, for instance, soaking.04-07-2011
20110098349CATHECHINS FOR THE TREATMENT OF SYSTEMIC AA AMYLOIDOSIS - A method of treating an amyloid disease characterized by AA amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AA amyloid fibrillogenesis in a mammalian subject.04-28-2011
20110178167METHOD FOR INHIBITING ACTIVITY AND/OR EXPRESSION OF MATRIX METALLOPROTEINASE, INHIBITING PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN KINASE, AND/OR PROMOTING EXPRESSION OF COLLAGEN USING TERMINALIA CATAPPA LEAF EXTRACT - A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided, and the method comprises administrating an effective amount of a 07-21-2011
20100029757USE OF XANTHOHUMOL AND/OR ISOXANTHOHUMOL AS AN AGENT FOR PREVENTING AND/OR COMBATING LIVER DISEASES - The present invention relates to the use of xanthohumol with formula (I) as an agent for the production of a preparations for preventing and/or combating liver diseases.02-04-2010
20100029758DERIVATIVES OF ISOFLAVONES - The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β.02-04-2010
20100022634Laidlomycin compositions and methods - An animal feed additive composition comprises an effective amount of a laidlomycin, a carrier, magnesium sulfate, and silicon dioxide. Other embodiments include methods of making the animal feed additive compositions, and the use of a laidlomycin in the manufacture of an animal feed additive for increasing the efficiency of feed utilization and rate of weight gain in domestic animals.01-28-2010
20110218240NOVEL COMPOUND WITH SPIRO CHIRAL CARBON BACKBONE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Provided are a novel compound with a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The novel compound with the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitory activity, and fatty acid synthesis inhibitory activity in the liver. Therefore, the novel compound can be expected to play an innovative role in treatment of osteoporosis, fatty liver, and obesity.09-08-2011
20100016421METHODS FOR DETERMINING SENSITIVITY TO AMINOFLAVONES - Methods and compositions for treating cancer are discussed herein. Specifically, methods for determining the sensitivity of a patient to treatment with therapeutic agents, compositions for treating patients, and the treatment methods thereof are provided.01-21-2010
20090176871Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones - The novel applicability and methods of use of soy germ extracted isoflavones for the treatment of sex hormone loss due to spaying, neutering and aging in domestic pets as well as service and guide animals.07-09-2009
20110077294R-(-) / S-(+)-7-[3-N SUBSTITUTED AMINO-2 HYDROXYPROPOXY] FLAVONES - The present invention provides an optically active compound of general formula (I) and salts thereof: wherein R′ is selected from a group consisting of t-butyl amine, n-butylamine, iso-butylamine, iso-propyl amine, 4-phenyl-piperazine-1-ylamine, 4-(2-methoxyphenyl)-piperazin-1-ylamine, and 3,4-dimethoxy phenethyl amine; wherein R03-31-2011
20100069481METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Isolated compounds and combinations of isolated compounds isolated from 03-18-2010
20090030069INSECT REPELLENT WITH SUN PROTECTION FACTOR - An insect repellent composition that includes a blend of either all natural oils or synthetic ingredients, a sunscreen vitamin F, volatile silicones to extend the effective repellent life of the spray and a film forming polymer to resist water wash off. The natural oils and extracts can include citronella and orange and the synthetics can include D-limonene and phtalic acid.01-29-2009
20100144857PRENYLFLAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.06-10-2010
20090069414Epicatechin and vasodilation - This invention relates to compositions comprising epicatechin and method of use of such compositions for inducing vasodilation of blood vessels in humans and veterinary animals.03-12-2009
20090076132ANTIVIRAL COMPOSITIONS AND METHODS OF TREATMENT - A composition and method of treatment of viruses in the Poxviridae family of infections and their associated symptoms using a tree extract out of which the majority (>90%) of dry mass are hydrolyzing flavonoids. Other extract components include taspine, dihydrobenzofuran lignan, phenols, steroids; and diterpenoids. The composition, flavokine, has been previously shown to treat various viral infections and their associated symptoms such as 03-19-2009
20110144195METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF - Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.06-16-2011
20110306661HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE AND DRUG RELEASE METHOD USING HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE - Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.12-15-2011
20090163579Novel use of nutraceutical compositions - The use of at least one component selected from the group consisting of EGCG, hydroxytyrosol, resveratrol and derivatives, metabolites or analogues thereof in the manufacture of a nutraceutical composition for the prevention and treatment of muscle wasting leading to muscle loss, atrophy and other associated muscle disorders in animals, in particular mammals including humans.06-25-2009
20110098348CANNABIS SATIVA PLANTS RICH IN CANNABICHROMENE AND ITS ACID, EXTRACTS THEREOF AND METHODS OF OBTAINING EXTRACTS THEREFROM - The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a botanical drug substance (BDS) and a purified BDS; • A formulation comprising the BRM, BDS, purified BDS or other extract; • The use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; • A method of deriving plants yielding a high proportion of the cannabinoid CBC (A) at the expense of other cannabinoids; • A method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and • A method of extracting CBC(A) from said plants.04-28-2011
20100173986SESQUITERPENES AND DERIVATIVES THEREOF FOR USE AS FEED ADDITIVES - The present invention relates to the use of sesquiterpenes and derivatives thereof as components of animal feed or feed additives for the improvement of animal performance as well as to the corresponding animal feed or feed additives containing them.07-08-2010
20120041059BIOACTIVE COMPOSITIONS FROM THEACEA PLANTS AND PROCESSES FOR THEIR PRODUCTION AND USE - The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting inflammatory activity in skin tissue of a mammal, for protecting skin tissue of a mammal from ultraviolet light-induced damage, and for normalizing skin disorders in skin tissue of a mammal. The present invention also relates to methods for isolating bioactive fractions derived from cell juice or a cell walls component a Theacea plant.02-16-2012
20110275707SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS - Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.11-10-2011
20100222422DIETARY SUPPLEMENTS CONTAINING EXTRACTS OF ARONIA AND METHODS OF USING SAME TO PROMOTE WEIGHT LOSS - A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.09-02-2010
20090093537Extracts rich in proanthocyanidins and relating process of preparation - The present invention relates to extracts containing high amounts of proanthocyanidins and the relating process of preparation involving the use as starting reactants of crushed fruits, plants or already prepurified extracts rich in proanthocyanidins.04-09-2009
20120046353CLEISTOCALYX OPERCULATUS-DERIVED COMPOUNDS HAVING INHIBITORY ACTIVITIES AGAINST AVIAN AND SWINE INFLUENZA VIRUSES OR NOVEL INFLUENZA VIRUS - The present invention relates to a 02-23-2012
20120004296CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.01-05-2012
20090258940American cranberry extract and its use - The present invention relates to an extract derived from 10-15-2009
20120208872USE OF TEA POLYPHENOLS FOR TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer.08-16-2012
20100010078METHODS OF TREATING ANDROGEN DEPENDENT PROSTATE CANCER BY ADMINISTERING AN ACTIVE PHARMACEUTICAL INGREDIENT BEING FISETIN, 3,3',4',7-TETRAHYDROXYFLAVONE OR A DERIVATIVE THEREOF, IN AN ORAL, TRANSDERMAL OR TOPICAL DOSAGE FORM - Administration of fisetin (3,3′,4′,7-tetrahydroxyflavone) to a human male to treat androgen dependent prostate cancer. Fisetin is found in fruits and vegetables, such as strawberry, apple, persimmon, grape, onion and cucumber. Fisetin treatment, through modulations in cki-cyclin-cdk network, inhibits PI3K and Akt resulting in inhibition of cell growth followed by apoptosis of human prostate cancer LNCaP cells.01-14-2010
20110054014PRENYLFLAVANONE COMPOUNDS AND USES THEREOF - The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.03-03-2011
20120252886CATECHINS FOR THE TREATMENT OF AMYLOIDOSIS - A method of treating an amyloid disease characterized by AL amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AL amyloid fibrillogenesis in a mammalian subject.10-04-2012
20120115941Compounds Affecting Glycemic Index - Compounds of formula I are disclosed which are useful as glycemic index lowering agents and/or, as α-amylase and/or α-glucosidase inhibitors. Also disclosed are nutritional and/or pharmaceutical compositions and supplements comprising one or more of these compounds. The compounds will be beneficial to patients who require stabilization of their postprandial glucose levels.05-10-2012
20110166219USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRECANCEROUS LESION OF THE SKIN - The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.07-07-2011
20110166218METHODS FOR MICRONIZATION OF HYDROPHOBIC DRUGS - The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.07-07-2011
20120059052PRENYLFLAVONOID FORMULATIONS - Methods and formulations for increasing the water solubility and/or bioavailability of prenylfiavonoids are disclosed. The formulations may be employed to treat a disease states, including cancer.03-08-2012
20120016016METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES - Disclosed herein, inter alia, are methods and compositions for treating a complication of diabetes or a vascular disease using a 5-desoxy-flavone and/or 5-desoxy-flavonol.01-19-2012
20120022152ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I):01-26-2012
20120022151METHOD FOR PREVENTING DAMAGE TO NUCLEAR MEMBRANE OF SKIN CELL BY ADMINISTERING AMENTOFLAVONE - Provided are a method for preventing damage to the nuclear membrane of skin cell including administering an effective amount of amentoflavone to a subject and a method for anti-aging including administering an effective amount of amentoflavone to a subject. By controlling the expression of defective lamin A induced by UV radiation or controlling the expression of phosphorylated H2A histone family, member X (H2AX) induced by UV radiation, the disclosed method prevents nuclear membrane damage and thus prevents skin cell damage. Accordingly, a composition containing amentoflavone as an active ingredient may be used as a cosmetic composition or a pharmaceutical composition.01-26-2012
20120115942Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith - Methods for synthesizing glycinols, glyceollins I and II, and isoflavene and chromane compounds using a Wittig reaction, compositions made therewith, and uses thereof are described.05-10-2012
20120059051ORAL COMPOSITION CONTAINING EGCG AND LYCOPENE - Composition containing the combination of (−)-epigallocatechin gallate (EGCG) and lycopene characterized in that the ratio of EGCG to lycopene is in the range of 100:1 to 1:1.03-08-2012
20120208873TEA POLYPHENOLS PRODUCTS FOR CEASING SMOKING AND TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of aiding smoking cessation and/or treating and/or preventing smoking addition or methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in aiding smoking cessation and/or treating and/or preventing smoking addition or treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer.08-16-2012
20110092586APOPTOSIS INDUCTOR EXTRACTED FROM POTATO, POTATO FOODSTUFF CONTAINING THE INDUCTOR, AND PROCESSED PRODUCT THEREOF - An apoptosis inductor is formed of an anthocyanin-containing extract obtained from a potato containing anthocyanine in the skin and flesh thereof. The potato is a potato of cultivated species, such as 04-21-2011
20120309821Use of epigallocatechin-3-gallate for immune regulation - The preset invention relates to a method for treating lupus erythematosus, particularly lupus nephritis, comprising administering a subject in need thereof a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients.12-06-2012
20110065784METHOD FOR PROMOTING GASTROINTESTINAL BICARBONATE SECRETION - Provided is a method for promoting gastrointestinal bicarbonate secretion in a mammalian subject, which comprises administering an effective amount of a compound of Formula (I):03-17-2011
20110065783HYDROXYLATED NEBIVOLOL METABOLITES - Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.03-17-2011
20120172423COMPOSITIONS AND METHODS FOR TREATING HERPES SIMPLEX VIRUS - Green tea polyphenol compositions and methods of their use in treating herpes simplex virus (HSV) are provided. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate as well as green tea polyphenols with one on more ester-linked fatty acids.07-05-2012
20080306143Cathechins for the Treatment of Fibrillogenesis in Alzheimer's Disease, Parkinson's Disease, Systemic AA Amyloidosis, and Other Amyloid Disorders - A method of treating an amyloid disease, or a disease characterized by alpha-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins or green tea extract. A pharmaceutical composition comprising a therapeutically effective amount of a catechin and a pharmaceutically acceptable excipient. The therapeutic amount of the catechin or green tea extract is selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.12-11-2008
20090131513ANTI-INFLAMMATORY MODALITIES - Anti-inflammatory modalities are described with reference to select isoflavonoid compounds, compositions containing same and the use of said compounds and/or compositions in treatment, particularly for the treatment of inflammatory diseases and related conditions.05-21-2009
20120122968USE OF DYNAMIN RING STABILIZERS - There is provided a method for promoting dynamin ring formation and/or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring formation has particular application in the prophylaxis or treatment of a kidney disease or condition characterized by proteinuria. A dynamin ring stabilizer can be any agent that interacts with dynamin to promote dynamin ring assembly and/or inhibit dynamin ring disassembly. There are also provided methods for prophylaxis or treatment of podocyte dysfunction and/or maintaining or inducing actin cytoskeleton formation in a cell utilizing dynamin ring stabilizers, and for screening a test agent for use as a dynamin ring stabilizer.05-17-2012
20120165403METHODS OF INHIBITING THE ACTIVITY OF HSP90 AND/OR ARYL HYDROCARBON RECEPTOR - The present invention relates to a method of screening compounds for binding to hsp90 by exposing a compound to hsp90 or a polypeptide fragment thereof containing amino acid residues 538-728 of the full length protein and determining whether the compound binds to hsp90 of the polypeptide fragment thereof. Also disclosed is a method of screening compounds for inhibition of hsp90 activity. The present invention further relates to a method of screening compounds as a cancer therapeutic and a method of treating cancerous conditions. Also disclosed is a method of inhibiting transcription-inducing activity of an aryl hydrocarbon receptor in a cell and a method of modifying expression of a gene that is activated by an aryl hydrocarbon receptor.06-28-2012
20120129923PHARMACEUTICAL CO-CRYSTALS OF QUERCETIN - Disclosed herein is synergistic pharmaceutical co-crystals composition comprising Quercetin and an antidiabetic agent(s) as combination drug that have unique physical properties and biological activity which differ from the active agent in pure form. The invention further discloses process for preparation of the same and pharmaceutical compositions comprising these synergistic co-crystals.05-24-2012
20120136047NEUROPROTECTIVE COMPOSITIONS AND METHODS - This disclosure concerns novel methods for preventing or treating neurological or neurodegenerative diseases or disorders by using kombo butter acid enriched extracts derived from the seeds of African nutmeg, the main active compounds isolated from the extracts, namely sargaquinoic acid, sargachromenol, and sargahydroquinoic acid, or synthetic analogs or derivatives thereof, as neuroprotective agents. The methods for preparing the kombo butter or kombo butter acid extracts and the methods for isolating and purifying the active compounds and for preparing their acetylated derivatives are also described.05-31-2012
20120136049ANTIBACTERIAL AGENT - The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R05-31-2012
20120136048TOPICAL, PERIOCULAR, OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES - A method for preventing, reducing, ameliorating or treating ophthalmic disorders associated with neurodegenerative diseases or trauma, comprising the topical, periocular, or intraocular application of an ophthalmic formulation comprising a therapeutically effective amount of one or more ophthalmic agents selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, or esters or mixtures thereof is disclosed. Use of tocotrienols for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are, or that are associated with, mitochondrial diseases is also discussed. Topical ophthalmic formulations comprising tocotrienols are also discussed.05-31-2012
20100173983METHOD FOR INDUCING AUTOPHAGY - The present invention relates to methods for inducing or promoting autophagy in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes autophagy in at least one cell of the subject.07-08-2010
20100173985Polyphenol proteasome inhibitors, synthesis, and methods of use - The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.07-08-2010
20100173984EPIGALLOCATECHIN-3-GALLATE CRYSTAL COMPOSITIONS - Crystalline epigallocatechin-3-gallate compositions and methods of use.07-08-2010
20100197779PHYTOESTROGENIC ISOFLAVONE COMPOSITIONS, THEIR PREPARATION AND USE THEREOF FOR PROTECTION AGAINST AND TREATMENT OF RADIATION INJURY - The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.08-05-2010
20100048689PROCESS OF OBTAINMENT OF SOY ISOFLAVONES - The present invention relates to the process for the recovery of conjugated isoflavones of residues and sub-products of food industries based on the use of soy and its derivatives. It also concerns of isoflavones obtained from food composition containing isoflavones and from the fungus genetically modified used in this process, 02-25-2010
20100273870COMPOSITIONS AND METHODS FOR TREATING DEMODEX INFESTATIONS - Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular 10-28-2010
20120178801COMPOSITIONS AND ITS USE IN TREATING OBESITY OR INDUCING WEIGHT LOSS - The present invention provides a composition comprising polyisoprenylated benzophenone derivative and at least one component selected from stilbene derivative and anthocyanins. The composition inhibits adipogenesis and is therefore useful in treating obesity or weight loss.07-12-2012
20100010079Proanthocyanidins for the Treatment of Amyloid and Alpha-Synuclein Diseases - A method of treating an amyloid disease, or a disease characterized by α-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed proanthocyanidins or a proanthocyanidin characterized by disclosed general formulae. A pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin and a pharmaceutically acceptable excipient. The therapeutic amount of the proanthocyanidin is selected for efficacy in treating amyloid, α-synuclein or NAC fibrillogenesis in a mammalian subject.01-14-2010
20100010077PROCESS FOR THE ADDITIVATION OF WINE - The present invention relates to a process for the additivation of wine, more specifically for the formation of compounds that are beneficial to health. The process is based on the contact of natural materials, namely cork, with wine, under conditions where certain compounds of the said materials react with other compounds present in the wine in order to form therein compounds with properties that are beneficial to the health of the consumer, namely a potent anti-cancerous agent called acutissimin-A. Additionally, the contact of the wine with the material also promotes the passage and interaction of compounds which will organoleptically influence the wine. The additivation process involves the contact with cork usually in fines particles, either at the final stage of vinification before bottling, during bottling or immediately before consumption, through different retention systems (filters, cartridges, etc.).01-14-2010
20110105600SYNERGISTIC COMPOSITION OF (-)-HYDROXYCITRIC ACID WITH MONOTERPENE AND A METHOD TO ENHANCE SATIETY - The present disclosure provides synergistic composition comprising (−)-hydroxycitric acid, its salts, amides and esters in conjunction with monoterpenes for enhancing satiety. The disclosure is also related to the use of synergistic composition in food and pharmaceutical compositions. The present disclosure helps in controlling obesity by enhancing satiety.05-05-2011
20120184605METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHEA - Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.07-19-2012
20120252887COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS - A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.10-04-2012
20120083524Oral Composition Comprising DHA and Genistein for Enhancing Skin Properties - Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the composition comprises genistein in an amount of from 0.0001% to 0.1% by 10 weight and the genistein and DHA exhibit an anti-ageing effect on skin.04-05-2012
20090018185COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.01-15-2009
20120259004ANTI-CANCER EXTRACT AND COMPOUNDS - The preset invention relates to a new approach for treating a cancer or fibrosis, such as Hepatocellular carcinoma, or liver fibrosis using an extract from a plant of 10-11-2012
20120264821USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES - Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.10-18-2012
20120264820Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of HIV infection and other pathologies - A compound, pharmaceutical composition and method for the treatment of mammals wherein the active therapeutic agent is a compound having the structure:10-18-2012
20090076130COMPOUNDS FOR THE INHIBITION OF HISTONE DEACETYLASE - The invention relates to a compound represented by the following formula (I):03-19-2009
20080300302Stabilized 3-Hydroxyflavan Compositions and Methods Therefor - Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione.12-04-2008
20110003889MEMBRANE FUSION INHIBITOR - The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R01-06-2011
20110003888HOPS EXTRACTION METHODS AND MIXTURES - Methods and mixtures for extracting prenylflavonoids from prenylflavonoid-containing hops materials are provided.01-06-2011
20090247622Natural topical compositions for the prevention and treatment of diaper rashes and related conditions - The treatment and prevention of skin irritations, including diaper rash, is facilitated with the topical application of cranberry anthocyanins in a cosmetically acceptable vehicle.10-01-2009
20110039924ALPHA-AMINO ACID DERIVATIVES FOR IMPROVING SOLUBILITY - The invention relates to the use of α-amino acid derivatives for improving the solubility of poorly soluble substances in water or aqueous solutions and to mixtures and preferred preparations.02-17-2011
20110046214COMPOSITION INHIBITING SEX HORMONE-BINDING GLOBULIN - A composition for inhibiting sex hormone-binding globulin, comprising isoflavones as active ingredients.02-24-2011
20120270932Personal Care Compositions with Improved Hyposensitivity - The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.10-25-2012
20120270931STABLE PHARMACEUTICAL FORMULATIONS COMPRISING LUBIPROSTONE - Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid.10-25-2012
20110213024TWO TYPES OF CRYSTALLINE OF PINOCEMBRIN, THEIR PREPARATION AND THEIR USE FOR MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS - Two crystalline forms of pinocembrin of formula (I): α and β, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.09-01-2011
20110237659CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS - The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.09-29-2011
20120277299METHOD FOR MODULATING ION TRANSPORTER - The present invention relates to a method for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising an administration at a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising a fatty acid derivative.11-01-2012
20120277303EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc.11-01-2012
20120277301CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS - Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.11-01-2012
20120277300COMPOSITIONS AND METHODS FOR INDUCING BONE GROWTH AND INHIBITING BONE LOSS - Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or neutered animals.11-01-2012
201001682237-Hydroxy Chromones As Potent Antioxidants - The present invention describes the identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising administering an effective amount of a 7-hydroxychrome or a mixture of 7-hydroxychromones. The present invention includes methods that are effective in inhibiting free radical and oxidation caused damage through the simultaneous suppression of free radical generation and the suppression of the production of reactive oxygen species (ROS). The present invention also includes methods for preventing and treating ROS mediated diseases and conditions and diseases and conditions associated with other oxidative processes. The method for preventing and treating ROS mediated diseases and conditions and diseases and conditions associated with other oxidative processes is comprised of administering to a host in need thereof an effective amount of a composition comprised of a 7-hydroxychrome or a mixture of 7-hydroxychromones and a pharmaceutically acceptable carrier. Included in this invention is an improved method to isolate and purify 7-hydroxychromones from plant sources.07-01-2010
20110281940METHOD OF PREPARATION AN INCLUSION-COMPLEX COMPRISING HYDROPHOBIC PHYSIOLOGICAL ACTIVATION MATERIAL INCLUDING WITH CYCLODEXTRIN AND ITS USE - Disclosed herein are a method for preparation of an inclusion-complex including a physiologically active hydrophobic substance in cjclodextrin and a derivative thereof, and use of the inclusion-complex prepared by the same. More particularly, the present invention provides a method for preparing an inclusion-complex, which includes agitating cjclodextrin and a derivative thereof in an agitator at high speed, spraying a physiologically active hydrophobic substance dissolved in alcohol onto the agitator, and drying and crushing the mixture obtained from the preceding step and, in addition, use of the prepared inclusion-complex. The present inventive method has merits of reduced inclusion time and increased inclusion rate. The prepared inclusion-complex has excellent cell and collagen proliferation effects compared to physiologically active hydrophobic substances which were not inclusion processed, thereby being used in production of a cosmetic composition with improved anti-wrinkle and anti-ageing effects.11-17-2011
201103194831-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I],12-29-2011
20110319482NOVEL TREATMENTS - The present invention relates to the treatment of the premonitory symptoms of migraine, to the treatment of aura associated with or without migraine, epilepsy, non-epileptic seizures, stroke or other cardiovascular disorders, to the pre-emptive treatment of aura, migraine, epilepsy, stroke or other cardiovascular disorders, to the treatment of migraine recurrence or aura recurrence, and to tonabersat, co-crystals thereof, and compositions comprising tonabersat for use in said treatments.12-29-2011
20120101152NEURITE ELONGATION AGENT, MEMORY-IMPROVING AGENT AND ANTI-ALZHEIMER AGENT COMPRISING 4'-DEMETHYLNOBILETIN OR 4'-DEMETHYLTANGERETIN AS ACTIVE INGREDIENT, AND PROCESS FOR PRODUCTION OF THE COMPOUND - A method for producing 4′-demethylnobiletin or 4′-demethyltangeretin including fermenting a skin derived from at least one citrus fruit selected from citrus fruits belonging to section 04-26-2012
20120329863ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA - The present disclosure provides compositions and methods for alleviating inflammatory-associated diseases and conditions. These methods include administering individual and/or a mixture of multiple flavans isolated from a single or multiple 12-27-2012
20120329862NOVEL COMPOUND HAVING INHIBITORY EFFECT ON LIPASE - This invention provides, a novel polyphenol compound having lipase inhibitory activity derived from tealeaves, a process for the preparation of the compound, and foods and/or beverages and pharmaceutical drugs containing the compound.12-27-2012
20100168222NOVEL USE OF SARGACHROMENOL - The present invention relates to novel use of sargachromenol, and more particularly, the present invention relates to novel use of sargachromenol for destroying and/or lysing hyperproliferating keratinocyte. Accordingly, since sargachromenol of the present invention has activity in destroying and/or lysing keratinocyte, it may be useful for keratinocyte lysing agents in the skin area where the keratinocytes are hyperproliferating or peeling agents.07-01-2010
20100168221PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B VIRUS AND HEALTH FOOD PRODUCT HAVING HEPATITIS B VIRUS INHIBITING EFFECTS - The invention provides a pharmaceutical composition for treating hepatitis B, including: an effective amount of proanthocyanidins; and a pharmaceutically acceptable carrier or salt, wherein a formula of the monomer of the proanthocyanidins is shown in the following:07-01-2010
20130012577PROCESS TO OBTAIN A STANDARDIZED EXTRACT OF QUERCETIN AND 3-O-METHYLQUERCETIN FROM INFLORESCENCES OF MACELA-DO-CAMPO, A COSMETIC, PHARMACEUTICAL AND VETERINARY COMPOSITION CONTAINING EXTRACT OF MACELA-DO-CAMPO, THE USE OF THIS EXTRACT AND THE METHOD OF APPLICATION OF THE AFORESAID EXTRACT - It describes an extraction process for obtaining a standardized extract of quercetin and 3-0-methylquercetin from inflorescences of macela-do-campo (01-10-2013
20100130598METHODS FOR INDUCING PROGRAMMED CELL DEATH - The present invention relates to methods for inducing or promoting caspase-independent apoptosis in a cell, the method comprising exposing to the cell an effective amount of a compound of formula I as described herein. The invention also relates to methods for treating or preventing diseases and disorders by administering to subjects in need thereof an effective amount of a compound of formula I, wherein the compound induces or promotes caspase-independent apoptosis in at least one cell of the subject.05-27-2010
20130018091TREATMENT OF ALLODYNIA AND HYPERALGESIA - The present invention relates to the treatment or prevention of allodynia and/or hyperalgesia, and to tonabersator an analogueof formula (1), and compositions comprising tonabersat or an analogue of formula (1) for use in said treatments.01-17-2013
20130023584Theaflavin Compositions, Related Processes and Methods of Use - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form.01-24-2013
20130023583Theaflavin Compositions, Related Processes and Methods of Use - A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form.01-24-2013
20090030071Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol - Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such as, but not limited to, hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention relates to methods for treating and/or preventing cardiovascular disorders in persons of Hispanic descent, particularly Mexican Americans, using compositions comprising nebivolol.01-29-2009
20080255227NOVEL COMPOSITION AND METHOD FOR STABILIZING THE SAME - Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.10-16-2008
20080255225Botanical Extract Composition - The invention relates to a kit comprising: a first composition comprising leaves of Melissa Officinalis, or parts thereof; a second composition comprising Eleutherococcus senticosus, or parts thereof; a third composition comprising Avena sativa, or parts thereof; a fourth composition comprising Ballota Nigra, or parts thereof; a third composition comprising the roots of Glycyrrhiza glabra/gan cao, or parts thereof; and a sixth composition comprising roots of Uncaria Tomentosa, or parts thereof. The invention further relates to a kit for use as a medicament, to a kit for use in the treatment of disorders in mammals, like humans, horses, cows, pigs and pets, to a kit for use in the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses, and to the use of the kit for the treatment of lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma in humans or tale and mane eczema in horses.10-16-2008
20080249164Antimicrobial and Antinflammatory Composition - The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.10-09-2008
20080234364COMPOSITION AND METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS - A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.09-25-2008
20080234363Antitumoral Compounds - Compounds of general formula (I), wherein R09-25-2008
20080234362Treatment for Asthma and Arthritis and Other Inflammatory Diseases - A synergistic effect is obtained in the treatment of combined omega-3 series polyunsaturated fatty acids and flavonoids in the treatment of asthma, chronic obstructive pulmonary disease, rheumatoid and osteoarthritis, and other inflammatory conditions. The fatty acids are extracted from the New Zealand Green Lipped Mussel 09-25-2008
20080227854Compound 3-(1, 1-Dimethyl-Allyl)-6-Hydroxy-Chromen-2-One and its Pharmaceutically Acceptable Salts Thereof - Accordingly the present invention describes the anti-inflammatory compound 3-(1,1-dimethyl-allyl)-6-hydroxy-chromen-2-one isolated from the 09-18-2008
20080221203Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease - Methods for treating and/or preventing cardiovascular diseases and diseases related thereto by administering a therapeutically effective amount of one or more first compound(s) having a beta3-adrenoceptor agonistic effect and a therapeutically effective amount of one or more second compound(s) having a beta1/beta2-adrenoceptor antagonistic effect are disclosed. The first compound(s) and the second compound(s) are used simultaneously, separately or sequentially as a combined preparation. Related cardiovascular diseases include arterial diseases, ischemic and failing cardiac diseases, including heart failure, conditions related to metabolic syndrome or angiogenesis-related disease. Pharmaceutical compositions are also described.09-11-2008
20130178517Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions - Disclosed are methods of treatment for adipogenic virus-related conditions. The methods may comprise administering a composition comprising an effective dose of an antiviral agent to a subject having an adipogenic adenovirus-related condition. Administration of the antiviral agent may prevent or reduce viral proliferation in the subject. The method may also include administering a composition comprising an effective dose of a therapeutic agent known to treat the adipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent. Administration of the antiviral agent and the therapeutic agent may reduce or eliminate one or more symptoms of the adipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent and the therapeutic agent alone.07-11-2013
20130096189USE OF GLABRANIN FOR STIMULATING HAIR GROWTH - One of the major hair concerns for both men and women is that of hair loss. For men the most obvious manifestation of this is male pattern baldness known as alopecia areata. However hair shedding resulting in hair thinning is also a concern for both men and women. Individuals suffering hair loss often experience psychological disadvantages, for example social phobia, anxiety, and depression, due to their change in appearance. This invention relates to a hair care composition comprising glabranin or a derivative thereof. The invention also relates to a cosmetic method for increasing hair fibre diameter, stimulating hair growth, retaining hair or reducing hair loss, stimulating hair follicle growth in anagen or telogen phases, increasing hair fibre density and preventing or treating alopecia.04-18-2013
20100286256COMPOSITIONS AND METHODS FOR THERAPY FOR DISEASES CHARACTERIZED BY DEFECTIVE CHLORIDE TRANSPORT - Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.11-11-2010
20100286255METHOD FOR EXTRACTING SECOISOLARICIRESINOL AND DIHYDROQUERCETIN FROM WOOD - The invention relates to extracting secoisolariciresinol and dihydroquercetin from wood. The inventive method consists in extracting disintegrating wood of a screen area by means of a non-splitting mixture of organic solvent and water, the solvent content ranging from 50 to 75%, in such a way that a secoisolariciresinol and dihydroquercetin-containing extract is obtained, and in processing said extract by removing the solvent in such a way that a final secoisolariciresinol and dihydroquercetin-containing mixture is obtained. In the other variant, the inventive method consists in extracting disintegrating wood of a screen area by means of a non-splitting mixture of organic solvent and water, the solvent content ranging from 50 to 75%, in such a way that a secoisolariciresinol and dihydroquercetin-containing extract is obtained, in processing said extract by removing the solvent in such a way that a final secoisolariciresinol and dihydroquercetin-containing mixture is obtained and in exposing the thus obtained mixture to selective extraction and crystallization in such a way that secoisolariciresinol and dihydroquercetin are extracted. In the third variant, the inventive method consists in extracting disintegrating wood of a screen area by means of a non-splitting mixture of organic solvent and water, the solvent content ranging from 50 to 75%, in such a way that an secoisolariciresinol and dihydroquercetin-containing extract is obtained, in processing said extract by removing non-polar components, in removing supernatant liquid, in chromatographing the obtained residue on a silica gel layer and in removing an eluent in such a way that a dry secoisolariciresinol and dihydroquercetin mixture is obtained. The use of secoisolariciresinol and dihydroquercetin in the form of components of biologically active additives and chemical-pharmaceutical products is also disclosed.11-11-2010
20110237660ORAL COMPOSITION - A composition which is adapted for oral consumption comprising daidzein and an anthocyanidin, wherein the weight ratio of daidzein to anthocyanidin is in the range of from 1:1 to 1:100, wherein the daidzein is in the form of a pre-prepared aqueous dispersion, and wherein the composition is free of soy protein, which can exhibit an anti-inflammatory effect in skin, the use of a composition containing daidzein and an anthocyanidin for obtaining an anti-inflammatory effect in the skin and a method of reducing skin inflammation through the oral consumption of the composition.09-29-2011
20130150435METHOD FOR TREATING HEPATITIS C - The disclosure provides a method for treating hepatitis C, including: administering an effective amount of a proanthocyanidins oligomer to a subject in need, wherein the structure of the proanthocyanidins oligomer is shown as Formula (I):06-13-2013
20110313034NEUROACTIVE PLANT EXTRACT FROM HYPERICUM POLYANTHEMUM - The present invention belongs to the field of plant extracts with activity on the central nervous system. Specifically, the plant extract of the present invention is an extract obtained from 12-22-2011
20130158106TOCOPHEROL DERIVATIVES AND METHODS OF USE - Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the α-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.06-20-2013
20120283322Rhus Verniciflua Stokes Extract Having Increased Content Of Active Flavonoid Compound And Method For Preparing Same - The present invention relates to 11-08-2012
20110288164AGENT FOR INHIBITING PRODUCTION OF HEPATITIS C VIRUS AND ITS USE - This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1),11-24-2011
20130190392METHOD OF PREPARING SOY ISOFLAVONE NANOPARTICLES BY PRECIPITATION WITH COMPRESSED ANTISOLVENT (PCA) USING A SUPERCRITICAL FLUID - The present invention relates to a method of preparing a solid form of soy isoflavone (e.g. genistein). In particular, the present invention relates to a method of preparing a solid form of soy isoflavone by precipitation with compressed antisolvent using a supercritical fluid to produce nano-sized particles of soy isoflavone with an improved dissolution rate and bioavailability. An oral composition or aerosolized formulation comprising the nanoparticles of the soy isoflavone prepared by the method of the present invention is also disclosed herein. The dissolution rate and bioavailability of the nanoparticles of the soy isoflavone prepared by the method of the present invention have a 2-fold increase and a 2.6-fold increase respectively as compared to those of the raw soy isoflavone.07-25-2013
20090062381AQUEOUS COMPOSITION - In an aqueous composition comprising a 15-keto-prostaglandin compound as an active ingredient, a polyoxyethylene castor oil derivative is admixed. By admixing a polyoxyethylene castor oil derivative, the solubility of the 15-keto-PG compound in water is increased. In a preferable embodiment, the aqueous composition may further comprise a quaternary ammonium type cationic surface active agent as a preservative. The composition of this embodiment exhibits high antimicrobial preservative effectiveness against indigenous bacterium in the eyes such as 03-05-2009
20120016015ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS - There is provided a method of conjugating a polymer containing a free aldehyde group with a flavonoid in the presence of an acid catalyst, such that the polymer is conjugated to the C6 or C8 position of the flavonoid A ring. The resulting conjugates may be used to form delivery vehicles to deliver high doses of flavonoids, and may also be used as delivery vehicles to deliver an additional bioactive agent.01-19-2012
20120029067Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use - The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.02-02-2012
20120029066USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS - Novel Use of flavones having 2-phenylchromen-4-one skeleton is disclosed herein. The flavones are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating a patient diagnosed with a psychiatric disorder with sensorimotor gating deficits.02-02-2012
20120029065COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.02-02-2012
20130197071PRODUCTION OF LIPOXYGENASE INHIBITORS VIA FUNGAL BIOSYNTHETIC PATHWAY - The invention provides methods for producing lipoxygenase inhibitors including the steps set forth in Schemes 2 and 3, and uses of the inhibitors produced by the methods set forth herein in to treat various disease states.08-01-2013
20130035380PROCESS FOR SELECTIVE EXTRACTION OF BIOACTIVE AND BIOAVAILABLE CINNAMON POLYPHENOLS AND PROCYANIDIN OLIGOMERS AND A STABLE COMPOSITION THEREOF - The present invention relates to a process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers of the type A and type B, of more than 90% purity as gallic acid equivalent which comprises the steps of removing the organic solvent from the extract to produce the free flowing oleoresin and drying of the residue under optimized conditions to produce a polyphenol and procyanidin Type A & B polymer rich solid which on subsequent extraction with water or with mixture of water and acetone or water and lower alcohol and further evaporation to a solid content of not more than 6% and subsequent chromatographic separation to obtain fractions containing procyanidin type A and B polymers free of coumarins and cinnamaldehyde. The present invention also relates to stable composition comprising cinnamon polyphenol rich powder for delivering maximum bioactivity upon oral administration.02-07-2013
20120088824DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.04-12-2012
20120095090NOVEL COMPOSITION AND METHOD FOR STABILIZING THE SAME - Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.04-19-2012
20130210907METHOD FOR PREVENTING OR TREATING ENTEROCHROMAFFIN CELL HYPERPLASIA-RELATED DISEASES BY QUERCETIN ADMINISTRATION - The present invention provides methods and compositions for preventing or treating enterochromatffin cell hyperplasia-related diseases. The compositions comprise a therapeutic effective amount of Quercetin, glycosylated Quercetin, or mixture thereof. The methods comprises administering said composition as well as preparing said composition as a pharmaceutical formulation,08-15-2013
20130210908STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc.08-15-2013
20130210909COUMARIN-CHALCONES AS ANTICANCER AGENTS - The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The present invention also relates to the process of preparation of the said compounds.08-15-2013

Patent applications in class Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)

Patent applications in all subclasses Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)